Source document: https://docs-lawep.s3.us-east-2.amazonaws.com/1698846991452.pdf (New Zealand)
2021/228 Medicines Amendment Regulations (No 2) 2021 Patsy Reddy, Governor-General Order in Council At Wellington this 30th day of August 2021 Present: The Right Hon Jacinda Ardern presiding in Council These regulations are made under section 105(1)(j) of the Medicines Act 1981— on the advice and with the consent of the Executive Council; and on the advice of the Minister of Health tendered after consultation with the organisations or bodies appearing to the Minister to be representative of per‐ sons likely to be substantially affected.
Contents Page (a) (b) Title Commencement Principal regulations Schedule 1 replaced Regulations revoked Schedule Schedule 1 replaced Regulations 1 Title These regulations are the Medicines Amendment Regulations (No 2) 2021.

1 2 2 2 2 3 1 Medicines Amendment Regulations (No 2) 2021 2021/228 Commencement These regulations come into force on 1 September 2021.

Principal regulations These regulations amend the Medicines Regulations 1984.
Schedule 1 replaced Replace Schedule 1 with the Schedule 1 set out in the Schedule of these regula‐ tions.

Regulations revoked The Medicines Amendment Regulations 2018 (LI 2018/179) are revoked.
r 2 2 3 4 5 2 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule Schedule Schedule 1 replaced Schedule 1 Prescription, restricted, and pharmacy-only medicines r 4 r 3 Every reference to a medicine in this schedule applies whether the medicine is syn‐ thetic in origin or is from biological or mineral sources.
Unless specific reference is made otherwise, every reference applies also to medicines that are— • • • • preparations and admixtures containing any proportion of any substance listed in this schedule: salts and esters of any substance listed in this schedule: preparations or extracts of biological materials listed in this schedule: salts or oxides of elements listed in this schedule.
Unless specific reference is made otherwise, every reference to a medicine in this schedule applies,— • • if the medicine is an injection or eye preparation, to any concentration of that medicine; and if the medicine is not an injection or eye preparation, only if the concentration of the medicine is greater than 10 milligrams per litre or per kilogram.
Where any reference is modified by a statement of the strength of the medicine, the strength is calculated using the free acid, base, alcohol, or element unless specifically stated otherwise.

Part 1 Prescription medicines Amending or replacing this Part may affect designated prescriber regulations under section 105(1)(q) of the Act.
19-norandrostenedione 2,4-dinitrochlorobenzene 4-aminopyridine 4-chloromethandienone 4-chlorotestosterone 5-aminolevulinic acid Abacavir 3 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 Abatacept Abciximab Abemaciclib Abiraterone Abrus precatorius; at all strengths Acamprosate Acarbose Acebutolol Acepromazine Acetanilides Acetarsol Acetazolamide Acetohexamide Acetylcarbromal Acetylcholine; except in medicines containing 1 milligram or less per litre or per kilogram Acetylcysteine; for injection or inhalation Acetyldigitoxin Acetylmethyldimethyloximidophenylhydrazine Acetylstrophanthidin Aciclovir; except when specified elsewhere in this schedule Acipimox Acitretin Aclidinium bromide Acokanthera ouabaio Acokanthera schimperi Aconitum spp; except when specified elsewhere in this schedule Acrivastine Adalimumab Adapalene; except in medicines containing 1 milligram or less per millilitre or gram and when supplied by a pharmacist in a pack containing not more than 30 grams for the treatment of comedo, popular, and pustular acne (acne vulga‐ ris) of the face, chest, or back Adefovir Adenosine; for injection 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule Adinazolam Adiphenine Adonis vernalis Adrafinil Adrenal extract; except for dermal use in medicines containing 0.02% or less of
 ketosteroids Adrenaline; in medicines containing more than 1% Adrenocortical hormones; except adrenal extract for dermal use containing 0.02% or less of ketosteroids Afamelanotide Afatinib Aflibercept Agalsidase Agomelatine Alatrofloxacin Albendazole Albumin; except human albumin Alclofenac Alclometasone; except when specified elsewhere in this schedule Alcohol; for injection in medicines containing more than 20% Alcuronium Aldesleukin Aldosterone; except in medicines containing 10 micrograms or less per litre or
 per kilogram Alectinib Alefacept Alemtuzumab Alendronic acid Alfacalcidol Alfentanil Alfuzosin Alglucerase Alglucosidase Alirocumab Aliskiren 5 Schedule Medicines Amendment Regulations (No 2) 2021 2021/ Alitretinoin Alkyl nitrites Alkyl sulfonals Allergens Allopurinol Allylisopropylacetylurea; at all strengths Allyloestrenol Alogliptin Aloracetam Alosetron Alpelisib Alpha1-proteinase inhibitor Alphadolone Alphaxalone Alprazolam Alprenolol Alprostadil Alseroxylon Alteplase Altretamine Amantadine Ambenonium Ambrisentan Ambucetamide Ambutonium Amcinonide Amethocaine; except when specified elsewhere in this schedule; for ophthal‐ mic use except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board Amfebutamone Amfepramone 100 Amidopyrine 101 Amifampridine 102 Amifostine 103 Amikacin 6 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule 104 Amiloride 105 Aminocaproic acid 106 Aminoglutethimide 107 Aminometradine 108 Aminophenazone; at all strengths 109 Aminophylline; except when specified elsewhere in this schedule 110 Aminopterin 111 Aminorex 112 Aminosalicylic acid 113 Amiodarone 114 Amiphenazole 115 Amisometradine 116 Amisulpride 117 Amitriptyline 118 Amlodipine 119 Ammi visnaga 120 Ammonium bromide 121 Amobarbital 122 Amodiaquine 123 Amorolfine; except when specified elsewhere in this schedule; except in prep‐ arations
 for the treatment of tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board 124 Amoxapine 125 Amoxycillin 126 Amphomycin 127 Amphotericin 128 Ampicillin 129 Amprenavir 130 Amrinone 131 Amsacrine 132 Amygdalin; at all strengths 133 Amyl nitrite; except when sold to a person who is appropriately authorised under the Health and Safety at Work Act 2015 134 Amylocaine 135 Anabolic steroids 7 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 136 Anagrelide 137
 Anakinra 138 Anastrozole 139 Ancestim 140 Anchusa officinalis; at all strengths 141 Ancrod and its immunoglobulin antidote 142 Androgenic and anabolic steroidal agents 143 Androgens 144 Androisoxazole 145 Androstanolone 146 Androstenediol 147 Androstenedione 148 Anecortave 149 Angiotensinamide 150 Anidulafungin 151 Aniracetam 152 Anistreplase 153 Antazoline; except for ophthalmic use 154 Antibiotic substances; except when specified elsewhere in this schedule 155 Antigens 156 Antihistamines; except when specified elsewhere in this schedule 157 Antimony; except in medicines containing 1 milligram or less per litre or per kilogram 158 Antisera; for injection 159 AOD-9604 160 Apalutamide 161 Apixaban 162 Apocynum spp 163 Apomorphine; except in medicines containing 1 milligram or less per litre or per kilogram 164 Apraclonidine 165 Apremilast 166 Aprepitant 167 Apronal 168 Aprotinin 8 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule 169 Arecoline 170 Aripiprazole 171 Aristolochia spp; at all strengths 172 Aristolochic acid; at all strengths 173 Armodafinil 174 Arsenic; except in medicines containing 1 milligram or less per litre or per kilogram 175 Artemether 176 Artemisia annua extract 177 Artesunate 178 Articaine; except when used as a local anaesthetic in practice by a dental thera‐ pist or oral health therapist registered with the Dental Council 179 Asenapine 180 Asfotase alfa 181 Asparaginase 182 Aspirin; except when specified elsewhere in this schedule; for
 injection; when combined with caffeine, paracetamol, or salicylamide 183 Astemizole 184 Asunaprevir 185 Atamestane 186 Atazanavir 187 Atenolol 188 Atezolizumab 189 Atomoxetine 190 Atorvastatin 191 Atosiban 192 Atovaquone 193 Atracurium 194 Atropa belladonna; except when specified elsewhere in this schedule; except in medicines containing 300 micrograms or less of total solanaceous alkaloids per litre or per kilogram 195 Atropine; except when specified elsewhere in this schedule; except when used as an
 antidote in a device designed for self-injection; except in medicines con‐ taining 300 micrograms or less per litre or per kilogram 196 Atropine methonitrate 197 Auranofin 9 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 198 Aurothiomalate sodium 199 Avanafil 200 Avelumab 201 Avibactam 202 Aviptadil 203 Axitinib 204 Azacitidine 205 Azacyclonol 206 Azapropazone 207 Azaribine 208 Azatadine; except when specified elsewhere in this schedule 209 Azathioprine 210 Azelaic acid; except when specified elsewhere in this schedule 211 Azelastine; except when specified elsewhere in this schedule 212 Azithromycin 213 Azlocillin 214 Aztreonam 215 Bacampicillin 216 Bacitracin 217 Baclofen 218 Baloxavir marboxil 219 Balsalazide 220 Bambuterol 221 Bamethan 222 Bamipine 223 Bamlanivimab 224 Barbital 225 Barbiturates 226 Baricitinib 227 Basiliximab 228 Bazedoxifene 229 Becaplermin 230 Beclamide 231 Beclomethasone; except when specified elsewhere in this schedule 232 Bedaquiline 10 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule 233 Belatacept 234 Belimumab 235 Bemegride 236 Benactyzine 237 Benazepril 238 Bendamustine 239 Bendrofluazide 240 Benethamine penicillin 241 Benorylate 242 Benoxaprofen 243 Benperidol 244 Benralizumab 245 Benserazide 246 Benzathine penicillin 247 Benzatropine 248 Benzbromarone 249 Benzhexol 250 Benzilonium 251 Benzocaine; except when specified elsewhere in this schedule 252 Benzodiazepine derivatives; except when specified elsewhere in
 this schedule 253 Benzodiazepines; except when specified elsewhere in this schedule 254 Benzoyl metronidazole 255 Benzoyl peroxide; except when specified elsewhere in this schedule 256 Benzthiazide 257 Benzydamine; except when specified elsewhere in this schedule 258 Benzylpenicillin 259 Bepridil 260 Beractant 261 Besifloxacin 262 Beta carotene; in medicines containing more than 18 milligrams per recom‐ mended daily dose 263 Betahistine 264 Betaine; for the treatment of homocystinuria 265 Betamethasone 266
 Betaxolol 11 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 267 Bethanechol 268 Bethanidine 269 Bevacizumab 270 Bevantolol 271 Bexarotene 272 Bezafibrate 273 Bezlotoxumab 274 Bicalutamide 275 Bictegravir 276 Bifonazole; except when specified elsewhere in this schedule 277 Bilastine; except when specified elsewhere in this schedule 278 Bimatoprost 279 Binimetinib 280 Biperiden 281 Bismuth; except for external use in medicines containing 3% or less 282 Bisoprolol 283 Bithionol; at all strengths 284 Bivalirudin 285 Bleomycin 286 Blinatumomab 287 Boceprevir 288 Bolandiol 289 Bolasterone 290 Bolazine 291 Boldenone 292 Bolenol 293 Bolmantalate 294 Boron, including borax and boric acid; except in medicines for internal use containing 6 milligrams or less per recommended daily dose; except in medi‐ cines for dermal use other than paediatric use containing 0.35% or less; except when present as an excipient 295 Bortezomib 296 Bosentan 297 Bosutinib 298 Botulinum toxins 12 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule 299 Brentuximab vedotin 300 Bretylium 301 Brexpiprazole 302 Brigatinib 303 Brimonidine 304 Brinzolamide 305 Brivaracetam (and its stereoisomers) 306 Brolucizumab 307 Bromazepam 308 Bromocriptine 309 Bromoform 310 Brompheniramine; except when specified elsewhere in this schedule 311 Bromvaletone 312 Brotizolam 313 Brugmansia spp 314 Buclizine; except for oral use 315 Budesonide; except when specified elsewhere in this schedule
 316 Bufexamac; except in suppositories; except for dermal use in medicines con‐ taining 5% or less 317 Bumetanide 318 Buniodyl sodium; at all strengths 319 Buphenine 320 Bupivacaine 321 Buprenorphine 322 Bupropion 323 Buserelin 324 Buspirone 325 Busulphan 326 Butacaine 327 Butobarbital 328 Butoconazole; except for vaginal use 329 Butorphanol 330 Butyl aminobenzoate; except in medicines for dermal use containing 2% or less 331 Butyl nitrite 13 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 332
 Butylchloral hydrate 333 Cabazitaxel 334 Cabergoline 335 Cabotegravir 336 Cabozantinib 337 Cacalia spp; at all strengths 338 Cadmium 339 Calcipotriol; except in medicines containing not more than 50 micrograms per gram or per millilitre and when sold in a pack of not more than 30 grams or 30 millilitres by a pharmacist to an adult with mild to moderate psoriasis previ‐ ously diagnosed by a doctor 340 Calcitonin 341 Calcitriol 342 Calcium carbimide 343 Calcium polystyrene sulphonate 344 Calotropis gigantea 345 Calotropis procera 346 Calusterone 347 Camazepam 348 Camphorated oil 349 Camphotamide 350 Canagliflozin 351 Canakinumab 352 Candesartan 353 Candicidin 354 Cannabidiol 355 Capecitabine 356 Capreomycin 357 Captodiame 358 Captopril 359 Capuride 360 Caramiphen 361 Carbachol 362 Carbamazepine 363 Carbaryl; except for external use in medicines containing 2% or less 14 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule 364 Carbazochrome 365 Carbenicillin 366 Carbenoxolone; except for external use 367 Carbetocin 368 Carbidopa 369 Carbimazole 370 Carbocromen 371 Carboplatin 372 Carboprost 373 Carbromal 374 Carbutamide 375 Carbuterol 376 Carfilzomib 377 Carglumic acid 378 Carindacillin 379 Carisoprodol 380 Carmustine 381 Carprofen 382 Carvedilol 383 Caspofungin 384 Catumaxomab 385 Cebaracetam (and its stereoisomers) 386 Cedazuridine 387 Cefacetrile 388 Cefaclor 389 Cefaloridine 390 Cefamandole 391 Cefapirin 392 Cefazolin 393 Cefepime 394 Cefetamet 395
 Cefixime 396 Cefodizime 397 Cefonicid 398 Cefoperazone 15 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 399 Cefotaxime 400 Cefotetan 401 Cefotiam 402 Cefoxitin 403 Cefpirome 404 Cefpodoxime 405 Cefsulodin 406 Ceftaroline fosamil 407 Ceftazidime 408 Ceftibuten 409 Ceftolozane 410 Ceftriaxone 411 Cefuroxime 412 Celecoxib 413 Celiprolol 414 Cenegermin 415 Cephaelis acuminata; except in medicines containing less than 0.2% of emetine 416 Cephaelis ipecacuanha; except in medicines containing less than
 0.2% of emet‐ ine 417 Cephalexin 418 Cephalothin 419 Cephradine 420 Ceritinib 421 Cerivastatin 422 Cerliponase alfa 423 Certolizumab pegol 424 Ceruletide 425 Cetirizine; except when specified elsewhere in this schedule 426 Cetrorelix 427 Cetuximab 428 Chenodeoxycholic acid 429 Chloral hydrate; except for dermal use in medicines containing 2% or less 430 Chloralformamide 431 Chloralose 432 Chlorambucil 16 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule 433 Chloramphenicol; except when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; except when specified elsewhere in this schedule 434 Chlorandrostenolone 435 Chlorazanil 436 Chlorcyclizine 437 Chlordiazepoxide 438 Chlormerodrin 439 Chlormethiazole 440 Chlormezanone 441 Chloroform; for anaesthesia; except when specified elsewhere in this schedule 442 Chloroquine 443 Chlorothiazide 444 Chlorotrianisene 445 Chloroxydienone 446 Chloroxymesterone 447 Chlorpheniramine; except when specified elsewhere in this schedule 448 Chlorphentermine 449 Chlorpromazine 450 Chlorpropamide 451 Chlorprothixene 452 Chlorquinaldol 453 Chlortetracycline 454 Chlorthalidone 455 Chlorzoxazone 456 Cholera vaccine; except in the form of an oral liquid containing vibrio cholerae when sold in a pharmacy by a registered pharmacist 457 Cholic acid 458 Choline salicylate; except in medicines containing 10% or less and in pack sizes of 15 grams or less 459 Chorionic gonadotrophin; except in
 pregnancy test kits 460 Chymopapain 461 Ciclacillin 462 Ciclesonide 463 Ciclopirox; except when specified elsewhere in this schedule 17 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 464 Cidofovir 465 Cilastatin 466 Cilazapril 467 Cilnidipine 468 Cilostazol 469 Cimetidine; except when specified elsewhere in this schedule 470 Cinacalcet 471 Cinchocaine; for injection; for ophthalmic use; for external use in medicines containing more than 0.5% 472 Cinchophen 473 Cinnarizine 474 Cinoxacin 475
 Ciprofloxacin 476 Cisapride 477 Cisatracurium 478 Cisplatin 479 Citalopram 480 CJC-1295 481 Cladribine 482 Clarithromycin 483 Clavulanic acid 484 Clemastine; except for oral use 485 Clemizole 486 Clenbuterol 487 Clevidipine 488 Clidinium 489 Clindamycin 490 Clioquinol; at all strengths 491 Clobazam 492 Clobetasol 493 Clobetasone; except when specified elsewhere in this schedule 494 Clocortolone 495 Clodronic acid 496 Clofarabine 497 Clofazimine 18 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule 498 Clofenamide 499 Clofibrate 500 Clomiphene 501 Clomipramine 502 Clomocycline 503 Clonazepam 504 Clonidine 505 Clopamide 506 Clopidogrel 507 Clorazepic acid 508 Clorexolone 509 Clorprenaline 510 Clostebol 511 Clotiazepam 512 Clotrimazole; except when specified elsewhere in this schedule 513 Cloxacillin 514 Cloxazolam 515 Clozapine 516 Cobalt 517 Cobicistat 518 Cobimetinib 519 Cocaine; except when specified elsewhere in this schedule 520 Codeine 521 Co-dergocrine 522 Colaspase 523 Colchicine 524 Colchicum 525 Colecalciferol; except in medicines containing 25 micrograms or less per rec‐ ommended daily dose; except in parenteral nutrition replacement preparations 526 Colestipol 527 Colestyramine 528 Colfosceril 529 Colistin 530 Collagen; in injections or implants for tissue augmentation or cosmetic use 531 Collagenase clostridium histolyticum 19 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 532 Coluracetam 533 Conium maculatum; at all strengths
 534 Convallaria keiski 535 Convallaria majalis 536 Corifollitropin alfa 537 Coronilla spp 538 Corticosterone 539 Corticotrophin 540 Cortisone and other steroidal hormones of the adrenal cortex; except when spe‐ cified elsewhere in this schedule; except adrenal extract for dermal use in med‐ icines containing 0.02% or less of ketosteroids 541 Cotarnine; at all strengths 542 Co-trimoxazole 543 Coumarin 544 COVID-19 vaccines; except when administered by vaccinators, registered pharmacists, or registered
 intern pharmacists who have successfully completed the COVID-19 Vaccinator Education Course (or any equivalent training course on COVID-19 vaccination approved by the Ministry of Health) and who com‐ ply with the immunisation standards of the Ministry of Health (but excluding vaccinators who have completed the Provisional Vaccinator Foundation Course or the COVID-19 Vaccinator - Working under Supervision Course) 545 Crisaborole 546 Crizotinib 547 Crofelemer 548 Crotalaria spp; at all strengths 549 Croton tiglium; except in medicines containing 1 milligram or less per litre or per kilogram 550 Crystal violet 551 Curare 552 Cyclandelate 553 Cyclizine; except when specified elsewhere in this schedule 554 Cyclobenzaprine 555 Cyclofenil 556 Cycloheximide 557 Cyclopenthiazide 558 Cyclopentolate; except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board 20 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule 559 Cyclophosphamide 560 Cyclopropane 561 Cycloserine 562 Cyclosporin 563 Cyclothiazide 564 Cycrimine 565 Cymarin 566 Cynoglossum spp; at all strengths 567 Cyproheptadine; except for oral use 568 Cyproterone 569 Cysteamine 570 Cytarabine 571 Dabigatran 572 Dabrafenib mesilate 573 Dacarbazine 574 Daclatasvir 575 Daclizumab 576 Dactinomycin 577 Dalfopristin 578 Dalteparin 579 Danaparoid 580 Danazol 581 Danthron 582 Dantrolene 583 Dapagliflozin 584 Dapoxetine 585 Dapsone 586 Daptomycin 587 Daratumumab 588 Darbepoetin
 589 Darifenacin 590 Darolutamide 591 Darunavir 592 Dasabuvir 593 Dasatinib 21 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 594 Datura spp; except for oral use when specified elsewhere in this schedule; except datura stramonium or datura tatula for smoking or burning 595 Daunorubicin 596 Deanol 597 Debrisoquine 598 Decamethonium 599 Decitabine 600 Deferasirox 601 Deferiprone 602 Defibrotide 603 Deflazacort 604 Degarelix 605 Dehydrochloromethyltestosterone 606 Dehydrocorticosterone 607
 Delavirdine 608 Delorazepam 609 Demecarium 610 Demeclocycline 611 Denosumab 612 Deoxycortone 613 Deoxycholic acid; for injection; except for oral use 614 Deoxyribonuclease; except for external use 615 Dermatophagoides farina allergen extract 616 Dermatophagoides pteronyssinus allergen extract 617 Desferrioxamine 618 Desflurane 619 Desipramine 620 Desirudin 621 Deslanoside 622 Desloratadine; except for oral use 623 Deslorelin 624 Desmopressin 625 Desogestrel; except when supplied for oral contraception to women who meet the clinical and eligbility criteria of the Pharmacy Council and the Pharmaceut‐ ical Society of New Zealand Incorporated approved training programme on 22 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule oral contraception, when sold in the manufacturer’s original pack that has received the consent of the Minister or Director-General to their distribution as medicines, containing not more than 6 months’ supply by a registered pharma‐ cist who has successfully completed the approved training programme 626 Desonide 627 Desoximetasone 628 Desvenlafaxine 629 Dexamethasone 630 Dexamfetamine 631 Dexchlorpheniramine; except when specified elsewhere in this schedule 632 Dexfenfluramine 633 Dexmedetomidine 634 Dextromethorphan; except when specified elsewhere in this schedule 635 Dextromoramide 636 Dextropropoxyphene 637 Dextrorphan 638 Di-iodohydroxy quinoline; except when specified elsewhere in this schedule 639 Di-isopropylamine dichloroacetate 640 Diazepam
 641 Diazoxide 642 Dibenzepin 643 Dibotermin 644 Dibrompropamidine; except for ophthalmic use 645 Dichloralphenazone 646 Dichlorophen 647 Dichlorphenamide 648 Diclofenac; in preparations for the treatment of solar keratosis; except when specified elsewhere in this schedule; except in preparations for topical use other than for the treatment of solar keratosis 649 Dicloxacillin 650 Dicyclomine 651 Didanosine 652 Dienoestrol 653 Dienogest 654 Diethazine 655 Diethylcarbamazine 23 Schedule Medicines Amendment
 Regulations (No 2) 2021 2021/228 656 Diethylstilbestrol 657 Diflorasone 658 Diflucortolone 659 Diflunisal 660 Digitalis lanata 661 Digitalis purpurea 662 Digitoxin 663 Digoxin 664 Digoxin-specific antibody fragment 665 Dihydralazine 666 Dihydrocodeine 667 Dihydroergotoxine 668 Dihydrolone 669 Dihydrotachysterol 670 Diltiazem 671 Dimenhydrinate; except when specified elsewhere in this schedule 672 Dimercaprol 673 Dimethandrostanolone 674 Dimethazine 675 Dimethindene; except for oral use 676 Dimethothiazine 677 Dimethoxanate 678 Dimethyl fumarate 679 Dimethyl sulphoxide 680 Dimiracetam (and its stereoisomers) 681 Dinitrocresols 682 Dinitronaphthols 683 Dinitrophenols 684 Dinitrothymols 685 Dinoprost 686 Dinoprostone 687 Diperodon 688 Diphemanil; except for dermal use 689 Diphenhydramine; except when specified elsewhere in this schedule 690 Diphenidol 24 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule 691 Diphenoxylate; except when specified elsewhere in this schedule 692 Diphenylpyraline 693 Diphtheria, tetanus, and pertussis (acellular, component) vaccine; except when administered in a single dose to a person 18 years of age or over or to a preg‐ nant woman aged 13 years or over by a registered pharmacist who has success‐ fully completed the Vaccinator Foundation Course (or any equivalent training course approved by the Ministry of Health) and who complies with the immu‐ nisation standards of the Ministry of Health (but excluding a vaccinator who has completed the
 Provisional Vaccinator Foundation Course) 694 Diphtheria toxoid 695 Diphtheria vaccine 696 Dipivefrin 697 Dipyridamole 698 Dirithromycin 699 Disopyramide 700 Distigmine 701 Disulfiram 702 Disulphamide 703 Ditiocarb 704 DMHA, including the isomers 2-amino-6-methylheptane (also known as 1,5- dimethylhexylamine, and octodrine) and 2-amino-5-methylheptane (also known as 1,4-dimethylhexylamine) 705 Dobutamine 706 Docetaxel 707 Dofetilide 708 Dolasetron 709 Doliracetam (and its stereoisomers) 710 Dolutegravir 711
 Domperidone 712 Donepezil 713 Dopamine 714 Dopexamine 715 Doravirine 716 Doripenem 717 Dornase 718 Dorzolamide 25 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 719 Dothiepin 720 Doxantrazole 721 Doxapram 722 Doxazosin 723 Doxepin 724 Doxorubicin 725 Doxycycline 726 Doxylamine; except when specified elsewhere in this schedule 727 Dronedarone 728 Droperidol 729 Drospirenone 730 Drostanolone 731 Drotrecogin 732 Duboisia leichhardtii; except when specified elsewhere in this schedule 733 Duboisia myoporides; except when specified elsewhere in this schedule 734 Dulaglutide 735 Dulcin; at all strengths 736 Duloxetine 737 Dupilumab 738 Dupracetam 739 Durvalumab 740 Dutasteride 741 Dydrogesterone 742 Econazole; except when specified elsewhere in this schedule 743 Ecothiopate 744 Ectylurea 745 Eculizumab 746 Edetic acid; except in medicines containing 0.25% or less; except in contact lens preparations; except dicobalt edetate for the treatment of cyanide poison‐ ing 747 Edoxudine 748 Edrophonium 749 Efalizumab 750 Efavirenz 751 Eflornithine 26 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule 752 Elbasvir 753 Eletriptan 754 Elosulfase alfa 755 Elotuzumab 756 Eltrombopag olamine 757 Eluxadoline 758 Elvitegravir 759 Emepronium 760 Emetine; except in medicines containing 0.2% or less 761 Emicizumab 762 Empagliflozin 763 Emtricitabine 764 Enalapril 765 Enasidenib 766 Encorafenib 767 Enestebol 768 Enflurane 769 Enfuvirtide 770 Enobosarm 771 Enoxacin 772
 Enoxaparin 773 Enoximone 774 Enprostil 775 Entacapone 776 Entecavir 777 Entrectinib 778 Enzalutamide 779 Ephedrine 780 Epicillin 781 Epinastine 782 Epirubicin 783 Epitiostanol 784 Eplerenone 785 Epoetins 786 Epoprostenol 27 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 787 Eprosartan 788 Eptifibatide 789 Erenumab 790 Ergocalciferol; except in medicines containing 25 micrograms or less per rec‐ ommended daily dose 791 Ergometrine 792 Ergot 793 Ergotamine 794 Ergotoxine 795 Eribulin 796
 Erlotinib 797 Ertapenem 798 Ertugliflozin 799 Erysimum spp; except in medicines containing 1 milligram or less per litre or per kilogram 800 Erythromycin 801 Erythropoietin 802 Escitalopram 803 Esketamine 804 Esmolol 805 Esomeprazole; except when specified elsewhere in this schedule 806 Estazolam 807 Estramustine 808 Estropipate 809 Etanercept 810 Ethacrynic acid 811 Ethambutol 812 Ethamivan 813 Ethanolamine; for injection 814 Ethchlorvynol 815 Ether; for anaesthesia; except when specified elsewhere in this schedule 816 Ethinamate 817 Ethinyloestradiol; except when supplied at a strength of 35 micrograms or less in combination with either levonorgestrel or norethisterone for oral contracep‐ tion to women who meet the clinical and eligibility criteria of the Pharmacy Council and the Pharmaceutical Society of New Zealand Incorporated 28 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule approved training programme on oral contraception, when sold in the manufac‐ turer’s original pack that has received the consent of the Minister or Director- General to their distribution as medicines, containing not more than 6 months’ supply by a registered pharmacist who has successfully completed the approved training programme 818 Ethionamide 819 Ethisterone 820 Ethoglucid 821 Ethoheptazine 822 Ethopropazine 823 Ethosuximide 824 Ethotoin 825 Ethoxzolamide 826 Ethyl chloride; for inhalation 827 Ethyl loflazepate 828 Ethyldienolone 829 Ethylhexanediol; at all strengths
 830 Ethyloestrenol 831 Ethynodiol 832 Etidocaine 833 Etidronic acid; except in medicines for external use containing 1% or less 834 Etilefrine 835 Etiracetam 836 Etodolac 837 Etofenamate; except for external use 838 Etomidate 839 Etonogestrel 840 Etoposide 841 Etoricoxib 842 Etravirine 843 Etretinate 844 Everolimus 845 Evolocumab 846 Exemestane 847 Exenatide 29 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 848 Ezetimibe 849 Factor VIII inhibitor bypassing fraction 850 Famciclovir; except
 when specified elsewhere in this schedule 851 Famotidine; except when specified elsewhere in this schedule 852 Fampridine 853 Farfugium japonicum; at all strengths 854 Fasoracetam (and its stereoisomers) 855 Febuxostat 856 Felbamate 857 Felbinac; except for external use 858 Felodipine 859 Felypressin; except when combined with a local anaesthetic and used in prac‐ tice by a dental therapist or oral health therapist registered with the Dental Council 860 Fenbufen 861 Fenclofenac 862 Fenfluramine 863 Fenofibrate 864 Fenoldopam 865 Fenoprofen 866 Fenoterol 867 Fenpipramide 868 Fenpiprane 869 Fentanyl 870 Ferric carboxymaltose 871 Ferric derisomaltose 872 Fexofenadine; except when specified elsewhere in this schedule 873 Fibrin 874 Fibrinolysin; except for external use 875 Fibroblast growth factor 876 Fidaxomicin 877 Filgrastim 878 Finasteride 879 Fingolimod 880 Flecainide 30 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule 881 Fleroxacin 882 Floctafenine 883 Fluanisone 884 Flubromazolam 885 Fluclorolone 886 Flucloxacillin 887 Fluconazole; except when specified elsewhere in this schedule 888 Flucytosine 889 Fludarabine 890 Fludiazepam 891 Fludrocortisone 892 Flufenamic acid 893 Flumazenil 894 Flumethasone 895 Flumethiazide 896 Flunarizine 897 Flunisolide 898 Flunitrazepam 899 Fluocinolone 900 Fluocinonide 901 Fluocortin 902 Fluocortolone 903 Fluorescein; for injection 904 Fluorides; for internal use in medicines containing more than 0.5 milligrams per dose
 unit except in medicines containing 15 milligrams or less per litre or per kilogram; except in parenteral nutrition replacement preparations; for exter‐ nal use in medicines containing more than 5.5 grams per litre or per kilogram except when supplied to a dental professional registered with the Dental Coun‐ cil 905 Fluorometholone 906 Fluorouracil 907 Fluoxetine 908 Fluoxymesterone 909 Flupenthixol 910 Fluphenazine 911 Flurandrenolone 31 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 912
 Flurazepam 913 Flurbiprofen; except when specified elsewhere in this schedule 914 Fluroxene 915 Fluspirilene 916 Flutamide 917 Fluticasone; except when specified elsewhere in this schedule 918 Fluvastatin 919 Fluvoxamine 920 Folic acid; except when specified elsewhere in this schedule 921 Folinic acid; except when specified elsewhere in this schedule 922 Follicle-stimulating hormone; except in medicines containing 100 micrograms or less per litre or per kilogram 923 Follistatin 924 Follitropin 925 Follitropin delta 926 Fomepizole 927 Fomivirsen 928 Fondaparinux 929 Fonturacetam (and its stereoisomers) 930 Formebolone 931 Formestane 932 Formoterol 933 Fosamprenavir 934 Fosaprepitant 935 Foscarnet 936 Fosfestrol 937 Fosfomycin 938 Fosinopril 939 Fosnetupitant 940 Fosphenytoin 941 Fotemustine 942 Framycetin 943 Fremanezumab 944 Fulvestrant 945 Furaltadone 32 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule 946 Furazabol 947 Furazolidone 948 Furosemide 949 Fusidic acid 950 Gabapentin 951 Galantamine 952 Galanthus spp 953 Galcanezumab 954 Gallamine 955 Galsulfase 956 Ganciclovir 957 Ganirelix 958 Gatifloxacin 959 Gefitinib 960 Gemcitabine 961 Gemeprost 962 Gemfibrozil 963 Gemifloxacin 964 Gemtuzumab ozogamicin 965 Gentamicin 966 Gestodene 967 Gestonorone 968 Gestrinone 969 Ghrelin 970 Gilteritinib 971 Gitalin 972 Glatiramer acetate 973 Glecaprevir 974 Glibenclamide 975 Glibornuride 976 Gliclazide 977 Glimepiride 978 Glipizide 979 Glisoxepide 980
 Glutathione; for injection 33 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 981 Glyceryl trinitrate; for injection; for transdermal use; except in medicines con‐ taining 100 micrograms or less per litre or per kilogram 982 Glycopyrronium 983 Glymidine 984 Golimumab 985 Gonadorelin 986 Gonadotrophic hormones; except when specified elsewhere in this schedule 987 Goserelin 988 Gramicidin 989 Granisetron 990 Grazoprevir 991 Grepafloxacin 992 Griseofulvin 993 Growth hormone releasing hormones 994 Growth
 hormone releasing peptide-6 995 Growth hormone releasing peptides 996 Guaifenesin; except when specified elsewhere in this schedule 997 Guanabenz 998 Guanethidine 999 Guanfacine 1000 Guanidine 1001 Guselkumab 1002 Hachimycin 1003 Haematin 1004 Haemophilus influenzae vaccine; except in oral vaccines for the prophylaxis of bacterial complications of colds 1005 Halazepam 1006 Halcinonide 1007 Halofantrine 1008 Halofenate 1009 Haloperidol; except in medicines containing 1 milligram or less per litre or per kilogram 1010 Halothane 1011 Haloxazolam 1012 Halquinol; except for external use 34 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule 1013 Heliotropium spp; at all strengths 1014 Hemerocallis 1015 Heparins; except when present as an excipient; except for external use 1016 Hepatitis A vaccine 1017 Hepatitis B vaccine 1018 Hetacillin 1019 Hexachlorophane; in medicines containing more than 3%; except when speci‐ fied elsewhere in this schedule 1020 Hexamethonium 1021 Hexarelin 1022 Hexetidine; except for external use 1023 Hexobendine 1024 Hexocyclium 1025 Hexoprenaline 1026 Hexaminolevulinate 1027 Histamine; except in medicines containing 0.5% or less 1028 Homatropine 1029 Human chorionic gonadotrophin; except in pregnancy test kits 1030 Human growth hormone secretagogues 1031 Human papillomavirus vaccine; except when administered by a registered pharmacist or registered intern pharmacist who has successfully completed the Vaccinator Foundation Course (or
 any equivalent training course approved by the Ministry of Health) and who complies with the immunisation standards of the Ministry of Health (but excluding a vaccinator who has completed the Pro‐ visional Vaccinator Foundation Course) 1032 Human protein C 1033 Hyaluronic acid; in injections or implants for tissue augmentation or cosmetic use 1034 Hydralazine 1035 Hydrargaphen 1036 Hydrochlorothiazide 1037 Hydrocortisone; except when specified elsewhere in this schedule 1038 Hydrocyanic acid; except when
 specified elsewhere in this schedule 1039 Hydroflumethiazide 1040 Hydromorphone 1041 Hydroquinone; except when specified elsewhere in this schedule 35 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 1042 Hydroxychloroquine 1043 Hydroxyephedrine 1044 Hydroxyphenamate 1045 Hydroxyprogesterone 1046 Hydroxystenozol 1047 Hydroxyurea 1048 Hydroxyzine 1049 Hylan polymer; in injections or implants for tissue augmentation or cosmetic use 1050 Hyoscine; except when specified elsewhere in this schedule; except in medi‐ cines containing 300 micrograms or less per litre or per kilogram 1051 Hyoscine butylbromide; except when specified elsewhere in this schedule 1052 Hyoscyamine; except when specified elsewhere in this schedule; except in medicines containing 300 micrograms or less per litre or per kilogram 1053 Hyoscyamus niger; except when specified elsewhere in this schedule 1054 Hypothalamic releasing factors 1055 Hypromellose; for injection; except in intraocular viscoelastic products 1056 Ibandronic acid 1057 Ibogaine 1058 Ibritumomab tiuxetan 1059 Ibrutinib 1060 Ibufenac 1061 Ibuprofen; except when specified elsewhere in this schedule 1062 Ibutamoren 1063 Ibuterol 1064 Ibutilide 1065 Icatibant 1066 Idarubicin 1067 Idarucizumab 1068 Idebenone 1069 Idelalisib 1070 Idoxuridine; except for dermal use in medicines containing 0.5% or less 1071 Idursulfase 1072 Ifosfamide 1073 Iloprost 36 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule 1074 Imatinib
 1075 Imiglucerase 1076 Imipenem 1077 Imipramine 1078 Imiquimod 1079 Immunoglobulins 1080 Imuracetam 1081 Indacaterol 1082 Indapamide 1083 Indinavir 1084 Indocyanine green 1085 Indomethacin; except when specified elsewhere in this schedule 1086 Indoprofen 1087 Indoramin 1088 Infliximab 1089 Influenza and coryza vaccines; for injection; for nasal use 1090 Influenza vaccine; except when administered to a person 13 years of age or over by vaccinators, registered pharmacists, or registered intern pharmacists
 who have successfully completed the Vaccinator Foundation Course (or any equivalent training course approved by the Ministry of Health) and who com‐ ply with the immunisation standards of the Ministry of Health (but excluding vaccinators who have completed the Provisional Vaccinator Foundation Course) 1091 Ingenol mebutate 1092 Inotuzumab ozogamicin 1093 Insulin degludec 1094 Insulin-like growth factors; except when specified elsewhere in this schedule 1095 Insulins 1096 Interferons 1097 Interleukins 1098 Iodothiouracil 1099 Ipamorelin 1100 Ipecacuanha; except when specified elsewhere in this schedule 1101 Ipilimumab 1102 Ipratropium; except for nasal use 1103 Ipriflavone 37 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 1104 Iprindole 1105 Iproniazid 1106 Irbesartan 1107 Irinotecan 1108 Iron; except when specified elsewhere in this schedule 1109 Isatuximab 1110 Isavuconazole 1111 Isoaminile 1112 Isoamyl nitrite 1113 Isobutyl nitrite 1114 Isocarboxazid 1115 Isoconazole; except when specified elsewhere in this schedule 1116 Isoetarine 1117 Isoflurane 1118 Isometheptene 1119 Isoniazid 1120 Isoprenaline 1121 Isoprinosine 1122 Isopropamide; except when specified elsewhere in this schedule 1123 Isosorbide dinitrate 1124 Isosorbide mononitrate 1125 Isotretinoin 1126 Isoxicam 1127 Isoxsuprine 1128 Isradipine 1129 Itraconazole 1130 Ivabradine 1131 Ivacaftor 1132 Ivermectin 1133 Ixabepilone 1134 Ixazomib 1135 Ixekizumab 1136 Japanese encephalitis vaccine 1137
 Juniperus sabina; at all strengths 1138 Kanamycin 38 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule 1139 Ketamine 1140 Ketanserin 1141 Ketazolam 1142 Ketoconazole; except when specified elsewhere in this schedule 1143 Ketoprofen; except when specified elsewhere in this schedule 1144 Ketorolac 1145 Ketotifen; except for ophthalmic use in medicines containing 0.025% or less 1146 Khellin 1147 Labetalol 1148 Lacidipine 1149 Lacosamide 1150 Lamivudine 1151 Lamotrigine 1152 Lanadelumab 1153
 Lanatosides 1154 Lanreotide 1155 Lansoprazole; except when specified elsewhere in this schedule 1156 Lanthanum 1157 Lapatinib 1158 Laronidase-rch 1159 Laropiprant 1160 Larotrectinib 1161 Latamoxef 1162 Latanoprost 1163 Laudexium 1164 Lauromacrogols; for injection 1165 Lead 1166 Ledipasvir 1167 Lefetamine 1168 Leflunomide 1169 Lenalidomide 1170 Lenograstim 1171 Lenvatinib 1172 Lepirudin 1173 Leptazol 39 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 1174 Lercanidipine 1175 Lesinurad 1176 Letermovir 1177 Letrozole 1178 Leucovorin; for injection 1179 Leuprorelin 1180 Levallorphan 1181 Levamisole 1182 Levetiracetam 1183 Levobunolol 1184 Levobupivacaine 1185 Levocabastine; except for nasal or ophthalmic use 1186 Levocetirizine; except for oral use 1187 Levodopa 1188 Levomepromazine 1189 Levomilnacipran 1190 Levonorgestrel; except when specified elsewhere in this schedule; except in medicines for use as emergency post-coital contraception when sold by nurses recognised by their professional body as having competency in the field of sex‐ ual and reproductive health; except when sold by nurses recognised by their professional body as having competency in the field of sexual and reproductive health; except when supplied for oral contraception to women who meet the clinical and eligibility criteria of the Pharmacy Council and the Pharmaceutical Society of New Zealand Incorporated approved training programme on oral contraception, when sold in the
 manufacturer’s original pack that has received the consent of the Minister or Director-General to their distribution as medi‐ cines, containing not more than 6 months’ supply by a registered pharmacist who has successfully completed the approved training programme 1191 Levosimendan 1192 Lidoflazine 1193 Lidocaine; for injection except when used as a local anaesthetic in practice by a nurse whose scope of practice permits the performance of general nursing functions or by a podiatrist registered with the Podiatrists
 Board or by a dental therapist or an oral health therapist registered with the Dental Council; for oph‐ thalmic use except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; for oral use except in throat loz‐ enges containing 30 milligrams or less per dose form; for external use in medi‐ cines containing more than 10%; except in throat sprays in medicines contain‐ ing 2% or less; except when specified elsewhere in this schedule 40 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule 1194 Lifitegrast 1195 Ligularia dentata; at all strengths 1196 Linaclotide 1197 Linagliptin 1198 Lincomycin 1199 Lindane; except for external use in medicines containing 2% or less 1200 Linezolid 1201 Liothyronine 1202 Lipegfilgrastim 1203 Liraglutide 1204 Lisdexamfetamine 1205 Lisinopril 1206 Lisuride 1207 Lithium; except when specified elsewhere in this schedule; except when present as an excipient in dermal medicines containing 0.25% or less 1208 Lixisenatide 1209 Lodoxamide; except in medicines for ophthalmic use 1210 Lofexidine 1211 Lomefloxacin 1212 Lomustine 1213 Loperamide; except when specified elsewhere in this schedule 1214 Lopinavir 1215 Loprazolam 1216 Loracarbef 1217 Loratadine; except when specified elsewhere in this schedule 1218 Lorazepam 1219 Lorlatinib 1220 Lormetazepam 1221 Losartan 1222 Loteprednol 1223 Lovastatin; except when present as an unmodified, naturally occurring sub‐ stance in a food that has
 not been subject to a manufacturing process other than heating, freezing, drying, preserving, bottling, canning, or packaging in retort pouches 1224 Loxapine 41 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 1225 Lumacaftor 1226 Lumefantrine 1227 Lumiracoxib 1228 Lurasidone 1229 Luteinising hormone 1230 Lymecycline 1231 Macitentan 1232 Mafenide 1233 Mannomustine 1234 Maprotiline 1235 Maraviroc 1236 Mazindol 1237 Measles vaccine; except when administered, in combination with mumps and rubella
 vaccines in a combination product the supply of which the Minister of Health has consented to, by vaccinators, registered pharmacists, or registered intern pharmacists who have successfully completed the Vaccinator Foundation Course (or any equivalent training course approved by the Ministry of Health) and who comply with the immunisation standards of the Ministry of Health (but excluding vaccinators who have completed the Provisional Vaccinator Foundation Course) 1238 Mebanazine 1239 Mebeverine 1240 Mebhydrolin 1241 Mebolazine 1242 Mebutamate 1243 Mecamylamine 1244 Mecasermin 1245 Mecillinam 1246 Meclocycline 1247 Meclofenamate 1248 Meclofenoxate 1249 Meclozine; except when specified elsewhere in this schedule 1250 Medazepam 1251 Medigoxin 1252 Medroxyprogesterone 1253 Medrysone 42 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule 1254 Mefenamic acid; except when specified elsewhere in this schedule 1255 Mefloquine 1256 Mefruside 1257 Megestrol 1258 Melagatran 1259 Melanocyte stimulating compounds 1260 Melatonin; except when supplied in medicines for oral use containing 3 milli‐ grams or less per immediate release dose unit, or 2 milligrams or less per modi‐ fied release dose unit, when sold in the manufacturer’s original pack that has received consent from the Minister of Health or the Director General for the treatment of primary insomnia for adults aged 55 years or older for up to 13 weeks by a registered pharmacist 1261 Meldonium 1262 Melengestrol 1263
 Melia azedarach; at all strengths 1264 Meloxicam 1265 Melphalan 1266 Memantine 1267 Meningococcal vaccine; except when administered to a person 16 years of age or over by a registered pharmacist who has successfully completed the Vacci‐ nator Foundation Course (or any equivalent training course approved by the Ministry of Health) and who complies with the immunisation standards of the Ministry of Health (but excluding a vaccinator who has completed the Provi‐ sional Vaccinator Foundation Course) 1268
 Menotrophin 1269 Mepacrine 1270 Mepenzolate 1271 Mephenesin 1272 Mephentermine 1273 Mepindolol 1274 Mepitiostane 1275 Mepivacaine 1276 Mepolizumab 1277 Meprobamate 1278 Meptazinol 1279 Mepyramine; except when specified elsewhere in this schedule 1280 Mequitazine 43 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 1281 Mercaptomerin 1282 Mercaptopurine 1283 Mercurochrome; except when specified elsewhere in this schedule 1284 Mercury; except when specified elsewhere in this schedule 1285 Meropenem 1286 Mersalyl 1287 Mesabolone 1288 Mesalazine 1289 Mesna 1290 Mestanolone 1291 Mesterolone 1292 Mestranol 1293 Metamfetamine 1294 Metamizole 1295 Metandienone 1296 Metaraminol 1297 Metenolone 1298 Metergoline 1299 Metformin 1300 Methacholine 1301 Methacycline 1302 Methadone 1303 Methallenoestril 1304 Methandriol 1305 Methanthelinium 1306 Methazolamide 1307 Methdilazine; except for oral use 1308 Methicillin 1309 Methimazole 1310 Methisazone 1311 Methixene 1312 Methocarbamol 1313 Methohexitone 1314 Methoin 1315 Methotrexate 44 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule 1316 Methoxamine; except when specified elsewhere in this schedule 1317 Methoxsalen 1318 Methoxyflurane 1319 Methsuximide 1320 Methyclothiazide 1321 Methyl aminolevulinate 1322 Methyl androstanolone 1323 Methyl clostebol 1324 Methyl mercury; except in medicines containing 300 micrograms or less per litre or per kilogram 1325 Methyl salicylate; except for external use; except
 for internal use when present as an excipient in medicines containing 1.04% or less per dose form 1326 Methyl trienolone 1327 Methyldopa 1328 Methylene blue; for injection 1329 Methylergometrine 1330 Methylhexanamine (1,3-dimethylamylamine (DMAA)); except when present as an unmodified, naturally occurring substance 1331 Methylnaltrexone 1332 Methylpentynol 1333 Methylphenidate 1334 Methylphenobarbital 1335 Methylphenylpiracetam 1336 Methylprednisolone 1337 Methyltestosterone 1338 Methylthiouracil 1339
 Methyprylon 1340 Methysergide 1341 Metoclopramide; except when specified elsewhere in this schedule 1342 Metolazone 1343 Metoprolol 1344 Metribolone 1345 Metrifonate 1346 Metronidazole 1347 Metyrapone 45 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 1348 Mexiletine 1349 Mezlocillin 1350 Mianserin 1351 Mibefradil 1352 Mibolerone 1353 Micafungin 1354 Miconazole; except when specified elsewhere in this schedule 1355 Midazolam 1356 Midodrine 1357 Midostaurin 1358 Mifepristone 1359 Migalastat 1360 Miglitol 1361 Miglustat 1362 Milnacipran 1363 Milrinone 1364 Minocycline 1365 Minoxidil; except for dermal use in medicines containing 5% or less 1366 Mirabegron 1367 Mirtazapine 1368 Misoprostol 1369 Mitobronitol 1370 Mitomycin 1371 Mitoxantrone 1372 Mitragyna speciosa 1373 Mitragynine 1374 Mivacurium 1375 Moclobemide 1376 Modafinil 1377 Molgramostim 1378 Molindone 1379 Molracetam 1380 Mometasone; except when specified elsewhere in this schedule 1381 Monobenzone 1382 Monoclonal antibodies; except in pregnancy test kits 46 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule 1383 Montelukast 1384 Moperone 1385 Morazone 1386 Moricizine 1387 Morphine; except when specified elsewhere in this schedule 1388 Motrazepam 1389 Motretinide 1390 Moxifloxacin 1391 Mumps vaccine; except when administered, in combination with measles and rubella vaccines in a combination product the supply of which the Minister of Health has consented to, by vaccinators, registered
 pharmacists, or registered intern pharmacists who have successfully completed the Vaccinator Foundation Course (or any equivalent training course approved by the Ministry of Health) and who comply with the immunisation standards of the Ministry of Health (but excluding vaccinators who have completed the Provisional Vaccinator Foundation Course) 1392 Mupirocin 1393 Muraglitazar 1394 Muromonab 1395 Mustine 1396 Mycophenolic acid 1397 Nabilone 1398 Nabumetone 1399 Nadolol 1400 Nadroparin 1401 Nafarelin 1402
 Naftidrofuryl 1403 Nalbuphine 1404 Nalidixic acid 1405 Nalmefene 1406 Nalorphine 1407 Naloxegol 1408 Naloxone; except when provided as part of an approved emergency kit for the treatment of opioid overdose 1409 Naltrexone 1410 Nandrolone 47 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 1411 Naproxen; except when specified elsewhere in this schedule 1412 Naratriptan 1413 Natalizumab 1414 Natamycin 1415 Nateglinide 1416 Nebacumab 1417 Nebivolol 1418 Nebracetam (and its stereoisomers) 1419 Nedocromil 1420 Nefazodone 1421 Nefiracetam 1422 Nefopam 1423 Nelfinavir 1424 Neomycin 1425 Neostigmine 1426 Nepafenac 1427 Nepidermin 1428 Neratinib 1429 Nerium oleander 1430 Nesiritide 1431 Netilmicin 1432 Netupitant 1433 Nevirapine 1434 Nialamide 1435 Nicardipine 1436 Nicergoline 1437 Nicofuranose 1438 Nicoracetam 1439 Nicorandil 1440 Nicotine; except when specified elsewhere in this schedule; except in prepar‐ ations for oromucosal or transdermal absorption; for nasal use except when sold from a smoking cessation clinic run under the auspices of a registered medical practitioner; in medicines other than for smoking cessation 1441 Nicotinic acid except nicotinamide; except when specified elsewhere in this schedule 48 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule 1442 Nicoumalone 1443 Nifedipine 1444 Nifenazone 1445 Nikethamide 1446 Nilotinib 1447 Nilutamide 1448 Nimesulide 1449 Nimetazepam 1450 Nimodipine 1451 Nimorazole 1452 Nintedanib 1453
 Niraparib 1454 Niridazole 1455 Nisoldipine 1456 Nitazoxanide 1457 Nitisinone 1458 Nitrazepam 1459 Nitrendipine 1460 Nitric oxide 1461 Nitrofurantoin 1462 Nitrofurazone 1463 Nitrous oxide; when supplied for inhalation 1464 Nitroxoline 1465 Nivolumab 1466 Nizatidine; except when specified elsewhere in this schedule 1467 Nomegestrol 1468 Nomifensine 1469 Noopept (and its stereoisomers) 1470 Noradrenaline 1471 Norandrostenolone 1472 Norbolethone 1473 Norclostebol 1474 Nordazepam 1475 Norelgestromin 1476
 Norethandrolone 49 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 1477 Norethisterone; except when supplied for oral contraception to women who meet the clinical and eligibility criteria of the Pharmacy Council and the Pharmaceutical Society of New Zealand Incorporated approved training pro‐ gramme on oral contraception, when sold in the manufacturer’s original pack that has received the consent of the Minister or Director-General to their distri‐ bution as medicines, containing not more than 6 months’ supply by a registered pharmacist who has successfully completed the approved training programme 1478 Norfloxacin 1479 Norgestrel 1480 Noribogaine 1481 Normethandrone 1482 Nortriptyline 1483 Noxiptyline 1484 Nusinersen 1485 Nux vomica; except in medicines containing 1 milligram or less per litre or per kilogram of strychnine 1486 Nystatin; except when specified elsewhere in this schedule 1487 Obeticholic acid 1488 Obinutuzumab 1489 Ocrelizumab 1490 Ocriplasmin 1491 Octamylamine 1492 Octatropine 1493 Octreotide 1494 Octyl nitrite 1495 Oestradiol; except in medicines containing 10 micrograms or less per litre or per kilogram 1496 Oestriol 1497 Oestrogens 1498 Oestrone; except in medicines containing 1 milligram or less per litre or per kilogram 1499 Ofatumumab 1500 Ofloxacin 1501 Olanzapine 1502 Olaparib 1503 Olaratumab 1504 Oleandomycin 50 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule 1505 Oleandrin 1506 Olmesartan 1507 Olodaterol 1508
 Olopatadine 1509 Olsalazine 1510 Omalizumab 1511 Omberacetam 1512 Ombitasvir 1513 Omeprazole; except when specified elsewhere in this schedule 1514 Ondansetron 1515 Opipramol 1516 Opium 1517 Orciprenaline 1518 Orlistat; except in medicines for weight control containing 120 milligrams or less per dose form 1519 Ornidazole 1520 Ornipressin 1521 Orphenadrine 1522 Orthopterin 1523 Oseltamivir; except when specified elsewhere in this schedule 1524 Osimertinib 1525 Otilonium bromide 1526 Ouabain 1527 Ovandrotone 1528
 Oxabolone 1529 Oxacillin 1530 Oxaliplatin 1531 Oxandrolone 1532 Oxaprozin 1533 Oxazepam 1534 Oxazolam 1535 Oxcarbazepine 1536 Oxedrine; except in medicines containing 30 milligrams or less per recommen‐ ded daily dose 1537 Oxetacaine; except for internal use 51 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 1538 Oxiconazole; except when specified elsewhere in this schedule 1539 Oxiracetam (and its stereoisomers) 1540 Oxitropium 1541 Oxolamine 1542 Oxolinic acid 1543 Oxpentifylline 1544 Oxprenolol 1545 Oxybuprocaine; except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board 1546 Oxybutynin 1547 Oxycodone 1548 Oxymesterone 1549 Oxymetholone 1550 Oxyphenbutazone 1551 Oxyphencyclimine 1552 Oxyphenisatin; at all strengths 1553 Oxyphenonium 1554 Oxytetracycline 1555 Oxytocin; except in medicines containing 1 microgram or less per litre or per kilogram 1556 Ozanimod 1557 Paclitaxel 1558 Palbociclib 1559 Palifermin 1560 Paliperidone 1561 Palivizumab 1562 Palonosetron 1563 Pamaquin 1564 Pamidronic acid 1565 Pancreatic enzymes; except in medicines containing 20 000 BP units or less of lipase activity 1566 Pancuronium 1567 Panitumumab 1568 Panobinostat 1569 Pantoprazole; except when specified elsewhere in this schedule 52 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule 1570 Papaveretum 1571 Papaverine; for injection 1572 Paracetamol; except when specified elsewhere in this schedule 1573 Paraldehyde
 1574 Paramethadione 1575 Paramethasone 1576 Parecoxib 1577 Paricalcitol 1578 Paritabprevir 1579 Paromomycin 1580 Paroxetine 1581 Pasireotide 1582 Patent blue V; for injection when used in diagnostic procedures 1583 Patiromer sorbitex calcium 1584 Pazopanib 1585 Pecazine 1586 Pefloxacin 1587 Pegaptanib 1588 Pegaspargase 1589 Pegfilgrastim 1590 Peginterferon 1591 Peginterferon beta-1a 1592 Pegvisomant 1593 Pembrolizumab 1594 Pemetrexed 1595 Pemoline 1596 Pempidine 1597 Penbutolol 1598 Penciclovir; except
 when specified elsewhere in this schedule 1599 Penicillamine 1600 Pentaerythrityl tetranitrate 1601 Pentagastrin 1602 Pentamethonium 1603 Pentamidine 1604 Pentazocine 53 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 1605 Penthienate 1606 Pentolinium 1607 Pentosan polysulfate sodium 1608 Pentostatin 1609 Pentoxifylline 1610 Peramivir 1611 Perampanel 1612 Pergolide 1613 Perhexiline 1614 Pericyazine 1615 Perindopril 1616 Permethrin; except in medicines containing 5% or less 1617 Perphenazine 1618 Pertussis antigen 1619 Pertussis (whooping cough) vaccine 1620 Pertuzumab 1621 Pethidine 1622 Phenacemide 1623 Phenacetin; except when present as an excipient 1624 Phenaglycodol 1625 Phenazone; except for external use 1626 Phenazopyridine 1627 Phenelzine 1628 Pheneticillin 1629 Phenformin 1630 Phenglutarimide 1631 Phenibut 1632 Phenindione 1633 Pheniramine; except when specified elsewhere in this schedule 1634 Phenisatin 1635 Phenobarbital 1636 Phenol; for injection 1637 Phenolphthalein 1638 Phenoperidine 1639 Phenoxybenzamine 54 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule 1640 Phenoxymethylpenicillin 1641 Phensuximide 1642 Phentermine 1643 Phenthimentonium 1644 Phentolamine 1645 Phenylbutazone 1646 Phenylephrine; except when specified elsewhere in this schedule 1647 Phenylpiracetam 1648 Phenylpropanolamine 1649 Phenyltoloxamine 1650 Phenytoin 1651 Phleum pratense extract 1652 Pholcodine; except when specified elsewhere in this schedule 1653
 Phosphodiesterase type 5 inhibitors; except when present as an unmodified, naturally occurring substance; except when specified elsewhere in this sched‐ ule 1654 Phthalylsulfathiazole 1655 Physostigmine 1656 Pibrentasvir 1657 Picibanil 1658 Picric acid 1659 Picrotoxin 1660 Pilocarpine; except in medicines containing 0.025% or less 1661 Pimecrolimus 1662 Pimozide 1663 Pinacidil 1664 Pinazepam 1665 Pindolol 1666 Pioglitazone 1667 Pipecuronium 1668 Pipemidic acid 1669 Pipenzolate 1670 Piperacetam 1671 Piperacillin
 1672 Piperidine 55 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 1673 Piperidolate 1674 Pipobroman 1675 Pipothiazine 1676 Pipradrol 1677 Piracetam 1678 Pirbuterol 1679 Pirenoxine 1680 Pirenzepine 1681 Piretanide 1682 Pirfenidone 1683 Piroxicam; except for external use 1684 Pirprofen 1685 Pitavastatin 1686 Pituitary hormones 1687 Pivampicillin 1688 Pizotifen 1689 Plerixafor 1690 Plicamycin 1691 Plitidepsin 1692 Pneumococcal vaccine; except in oral vaccines for the prophylaxis of bacterial complications of colds 1693 Podophyllotoxin; for internal use; for external use for the treatment of anogeni‐ tal warts; for other external use in medicines containing more than 1%; except in medicines containing 1 milligram or less of podophyllin per litre or per kilo‐ gram 1694 Podophyllum emodi; for internal use; for external use for the treatment of ano‐ genital warts; for other external use in medicines containing more than 20% of podophyllin; except in medicines containing 1 milligram or less of podophyllin per litre or per kilogram 1695 Podophyllum peltatum; for internal use; for external use for the treatment of anogenital warts; for other external use in medicines containing more than 20% of podophyllin; except in medicines containing 1 milligram or less of podo‐ phyllin per litre or per kilogram 1696 Polatuzumab vedotin 1697 Polidexide 1698 Poliomyelitis vaccine 56 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule 1699 Polyacrylamide; in
 injections or implants for tissue augmentation or cosmetic use 1700 Polyestradiol 1701 Polylactic acid; in injections or implants for tissue augmentation or cosmetic use 1702 Polymyxin 1703 Polysulfated glycosaminoglycans; for injection except in intraocular viscoelas‐ tic products 1704 Polythiazide 1705 Pomalidomide 1706 Ponatinib 1707 Poractant alfa 1708 Posaconazole 1709 Potassium bromide 1710 Potassium perchlorate 1711 Practolol 1712 Pradofloxacin 1713 Pralatrexate 1714 Pralidoxime 1715 Pralmorelin 1716
 Pramipexole 1717 Pramiracetam 1718 Pramocaine 1719 Prampine 1720 Prasterone 1721 Prasugrel 1722 Pravastatin 1723 Prazepam 1724 Praziquantel 1725 Prazosin 1726 Prednisolone 1727 Prednisone 1728 Pregabalin 1729 Pregnenolone 1730 Prenalterol 57 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 1731 Prenylamine 1732 Prilocaine; for injection except when used as a local anaesthetic in practice by a dental therapist or an oral therapist registered with the Dental Council; except when specified elsewhere in this schedule 1733 Primaquine 1734 Primidone 1735 Probenecid 1736 Probucol 1737 Procainamide 1738 Procaine 1739 Procaine penicillin 1740 Procarbazine 1741 Prochlorperazine; except when specified elsewhere in this schedule; except when sold for the treatment of nausea associated with emergency contraception by pharmacists or nurses accredited to sell levonorgestrel for emergency con‐ traception 1742 Procyclidine; except for dermal use in medicines containing 5% or less 1743 Progesterone; except in medicines containing 1 milligram or less per litre or per kilogram 1744 Progestogens 1745 Proglumide 1746 Proguanil 1747 Prolintane 1748 Promazine 1749 Promethazine; except when specified elsewhere in this schedule 1750 Promoxolane 1751 Propafenone 1752 Propamidine; except for ophthalmic use 1753 Propanidid 1754 Propantheline 1755 Propetandrol 1756 Propionibacterium acnes 1757 Propofol 1758 Propranolol; except in medicines containing 1 milligram or less per litre or per
 kilogram 1759 Propylthiouracil 58 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule 1760 Propyphenazone 1761 Proquazone 1762 Proscillaridin 1763 Prostaglandins 1764 Protamine 1765 Prothionamide 1766 Prothipendyl 1767 Protirelin 1768 Protoveratrines 1760 Protriptyline 1770 Proxymetacaine; except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board 1771 Prucalopride 1772 Pseudoephedrine 1773 Pulmonaria spp; at all strengths 1774 Pyrazinamide 1775
 Pyridinolcarbamate 1776 Pyridostigmine 1777 Pyridoxal; except in medicines containing 200 milligrams or less per recom‐ mended daily dose 1778 Pyridoxamine; except in medicines containing 200 milligrams or less per rec‐ ommended daily dose 1779 Pyridoxine; except in medicines containing 200 milligrams or less per recom‐ mended daily dose 1780 Pyrimethamine 1781 Pyrvinium 1782 Quazepam 1783 Quetiapine 1784 Quinagolide 1785 Quinapril 1786 Quinbolone 1787 Quinethazone 1788 Quinidine 1789 Quinine; except in medicines containing 50 milligrams or less per recommen‐ ded daily dose 1790 Quinisocaine 59 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 1791 Quinupristin 1792 Rabeprazole 1793 Rabies vaccine 1794 Racetams; except when specified elsewhere in this schedule 1795 Raloxifene 1796 Raltegravir 1797 Raltitrexed 1798 Ramipril 1799 Ramucirumab 1800 Ranibizumab 1801 Ranitidine; except when specified elsewhere in this schedule 1802 Ranolazine 1803 Rapacuronium 1804 Rasagiline 1805 Rasburicase 1806 Rauwolfia serpentina 1807 Rauwolfia vomitoria 1808 Razoxane 1809 Reboxetine 1810 Recombinant human epidermal growth factor 1811 Recombinant varicella zoster virus glycoprotein E antigen 1812 Regorafenib 1813 Remdesivir 1814 Remestemcel-L 1815 Remifentanil 1816 Remoxipride 1817 Repaglinide 1818 Reserpine 1819 Reslizumab 1820 Retapamulin 1821 Reteplase 1822 Retigabine 1823 Ribavirin 1824 Ribociclib 1825 Ridaforolimus 60 2021/228 Medicines Amendment Regulations (No 2)
 2021 Schedule 1826 Rifabutin 1827 Rifampicin 1828 Rifamycin 1829 Rifapentine 1830 Rifaximin 1831 Rilmazafone 1832 Rilpivirine 1833 Riluzole 1834 Rimexolone 1835 Rimiterol 1836 Rimonabant 1837 Riociguat 1838 Ripretinib 1839 Risankizumab 1840 Risedronic acid 1841 Risperidone 1842 Ritodrine 1843 Ritonavir 1844 Rituximab 1845 Rivaroxaban 1846 Rivastigmine 1847 Rizatriptan; except when specified elsewhere in this schedule 1848 Rocuronium 1849 Rofecoxib 1850 Roflumilast 1851 Rolipram (and its stereoisomers) 1852
 Rolitetracycline 1853 Rolziracetam 1854 Romidepsin 1855 Romiplostim 1856 Romosozumab 1857 Ropinirole 1858 Ropivacaine 1859 Rosiglitazone 1860 Rosoxacin 61 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 1861 Rosuvastatin 1862 Rotavirus vaccine 1863 Rotigotine 1864 Roxibolone 1865 Roxithromycin 1866 Rubella vaccine; except when administered, in combination with measles and mumps vaccines in a combination product the supply of which the Minister of Health has consented to, by vaccinators, registered pharmacists, or registered intern pharmacists who have successfully completed the Vaccinator Foundation Course (or any equivalent training course approved by the Ministry of Health) and who complies with the immunisation standards of the Ministry of Health (but excluding vaccinators who have completed the Provisional Vaccinator Foundation Course) 1867 Ruboxistaurin 1868 Rufinamide 1869 Rupatadine 1870 Ruxolitnib 1871 Sabadilla; except in preparations containing 10 milligrams or less of total alka‐ loids of schoenocaulon officinale per litre or per kilogram 1872 Sacubitril 1873 Safinamide 1874 Safrole; for internal use except in medicines containing 0.1% or less 1875 Salbutamol 1876 Salcatonin 1877 Salmeterol 1878 Sapropterin 1879 Saquinavir 1880 Sargramostim 1881 Sarilumab 1882 Saxagliptin 1883 Schoenocaulon officinale; except in preparations containing 10 milligrams or less of total alkaloids of schoenocaulon officinale per litre or per kilogram 1884 Scopolia
 carniolica 1885 Sebelipase alfa 1886 Secbutabarbital 1887 Secobarbital 1888 Secukinumab 62 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule 1889 Selective androgen receptor modulators 1890 Seletracetam (and its stereoisomers) 1891 Selegiline 1892 Selenium; except when specified elsewhere in this schedule; except for oral use in medicines containing 150 micrograms or less per recommended daily dose 1893 Selexipag 1894 Semaglutide 1895 Serelaxin 1896 Sermorelin 1897 Sertindole 1898 Sertraline
 1899 Serum, dried human 1900 Sevelamer 1901 Sevoflurane 1902 Sex hormones and all substances having sex hormone activity 1903 Sialoepoetin 1904 Sibutramine 1905 Silandrone 1906 Sildenafil and its structural analogues; except sildenafil in medicines for oral use containing 100 milligrams or less per dose unit when sold in the manufac‐ turer’s original pack containing not more than 12 solid dosage units for the treatment of erectile dysfunction in males aged 35–70 years by a registered pharmacist who has successfully completed a training programme endorsed by the Pharmaceutical Society of New Zealand Incorporated 1907 Silicones; for injection 1908 Silodosin 1909 Siltuximab 1910 Silver sulfadiazine; except for external use in packs containing 50 grams or less 1911 Simeprevir 1912 Simvastatin 1913 Siponimod 1914 Sirolimus 1915 Sisomicin 1916 Sitagliptin 1917 Sitaxentan 1918 Sodium bromide 63 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 1919 Sodium cellulose phosphate; for internal use 1920 Sodium cromoglycate; except for nasal and ophthalmic use 1921 Sodium morrhuate; for injection 1922 Sodium nitroprusside 1923 Sodium phenylbutyrate 1924 Sodium phosphate; in oral laxative preparations 1925 Sodium polystyrene sulphonate 1926 Sodium tetradecyl sulphate; for injection 1927 Sodium zirconium cyclosilicate 1928 Sofosbuvir 1929 Solasadine 1930 Solifenacin 1931 Somatostatin 1932 Somatropin 1933 Sonidegib 1934 Sontoquine 1935 Sorafenib 1936 Sotalol 1937
 Sparfloxacin 1938 Sparteine 1939 Spectinomycin 1940 Spiramycin 1941 Spirapril 1942 Spironolactone 1943 Squill 1944 Stanolone 1945 Stanozolol 1946 Staphylococcus aureus vaccine; except in oral vaccines for the prophylaxis of bacterial complications of colds 1947 Stavudine 1948 Stenabolic (SR9009) and other synthetic REV-ERB agonists 1949 Stenbolone 1950 Steroid hormones 1951 Stilboestrol 1952 Stiripentol 64 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule 1953 Stramonium; except for oral use when
 specified elsewhere in this schedule; except datura stramonium or datura tatula for smoking or burning 1954 Streptococcus beta-haemolyticus vaccine; except in oral vaccines for the pro‐ phylaxis of bacterial complications of colds 1955 Streptodornase 1956 Streptokinase 1957 Streptomycin 1958 Streptozocin 1959 Strontium ranelate 1960 Strophanthins 1961 Strophanthus spp 1962 Strychnos spp; except in medicines containing 1 milligram or less per litre or per kilogram of strychnine 1963 Styramate 1964 Succimer 1965 Sufentanil 1966 Sugammadex 1967 Sulbactam 1968 Sulconazole; except for dermal use 1969 Sulfacetamide; except for ophthalmic use in medicines containing 10% or less 1970 Sulfadiazine; except silver sulfadiazine for external use in pack sizes of 50 grams or less 1971 Sulfadimethoxine 1972 Sulfadimidine 1973 Sulfadoxine 1974 Sulfafurazole 1975 Sulfaguanidine 1976 Sulfamerazine 1977 Sulfamethizole 1978 Sulfamethoxazole 1979 Sulfamethoxydiazine 1980 Sulfamethoxypyridazine 1981 Sulfametrole 1982 Sulfamonomethoxine 1983 Sulfamoxole 65 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 1984 Sulfaphenazole 1985 Sulfapyridine 1986 Sulfasalazine 1987 Sulfathiazole 1988 Sulfatroxazole 1989 Sulfinpyrazone 1990 Sulfomyxin 1991 Sulfonmethane 1992 Sulindac 1993 Sultamicillin 1994 Sulthiame 1995 Sumatriptan; except when specified elsewhere in this schedule 1996 Sunifiram 1997 Sunitinib 1998 Suprofen 1999 Suvorexant 2000 Sutilains 2001 Suxamethonium 2002 Suxethonium 2003
 T cell receptor antibody 2004 Tacrine 2005 Tacrolimus 2006 Tadalafil and its structural analogues 2007 Tafamidis 2008 Tafenoquine succinate 2009 Tafluprost 2010 Talazoparib 2011 Taliglucerase alfa 2012 Talimogene laherparepvec 2013 Tamoxifen 2014 Tamsulosin 2015 Tanacetum vulgare; except in medicines containing 0.8% or less of oil of tansy 2016 Tapentadol 2017 Tasonermin 2018 Tazarotene 66 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule 2019 Tazobactam 2020 Teduglutide 2021 Tegafur 2022
 Tegaserod 2023 Teicoplanin 2024 Telaprevir 2025 Telbivudine 2026 Telithromycin 2027 Telmisartan 2028 Telotristat ethyl 2029 Temazepam 2030 Temozolomide 2031 Temsirolimus 2032 Tenecteplase 2033 Teniposide 2034 Tenofovir 2035 Tenoxicam 2036 Terazosin 2037 Terbinafine; except when specified elsewhere in this schedule 2038 Terbutaline 2039 Terfenadine 2040 Teriflunomide 2041 Teriparatide 2042 Terlipressin 2043 Terodiline 2044 Teropterin 2045 Tesamorelin 2046 Testolactone 2047 Testosterone; except in medicines containing 1 milligram or less per litre or per kilogram 2048 Tetanus antitoxin 2049 Tetanus toxoid 2050 Tetanus vaccine 2051 Tetrabenazine 2052 Tetracosactrin 67 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 2053 Tetracycline 2054 Tetraethylammonium 2055 Tetrahydrocannabinol 2056 Tetrazepam 2057 Tetroxoprim 2058 Thalidomide 2059 Thenyldiamine 2060 Theophylline; except when specified elsewhere in this schedule 2061 Thevetia peruviana 2062 Thevetin 2063 Thiambutosine 2064 Thiazosulfone 2065 Thiethylperazine 2066 Thioacetazone 2067 Thiocarlide 2068 Thioguanine 2069 Thiomesterone 2070 Thiopentone 2071 Thiopropazate 2072 Thioproperazine 2073 Thioridazine 2074 Thiotepa 2075 Thiothixene 2076 Thiouracil 2077 Thiourea; except in medicines containing 0.1% or less 2078 Thymosin beta-4 2079 Thymoxamine 2080 Thyroid 2081 Thyrotrophin 2082 Thyrotrophin-releasing factor 2083 Thyroxine; except in medicines containing 10 micrograms or less per litre or per kilogram
 2084 Tiagabine 2085 Tianeptine 2086 Tiaprofenic acid 68 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule 2087 Tiaramide 2088 Tibolone 2089 Ticagrelor 2090 Ticarcillin 2091 Ticlopidine 2092 Tiemonium 2093 Tienilic acid 2094 Tigecycline 2095 Tigloidine 2096 Tiletamine 2097 Tilidine 2098 Tilmanocept 2099 Tiludronic acid 2100 Timbetasin 2101 Timolol 2102 Tinidazole 2103 Tinzaparin 2104 Tioconazole; except when specified elsewhere in this schedule 2105 Tiotropium 2106 Tipepidine 2107 Tipiracil
 2108 Tiprinavir 2109 Tirilazad 2110 Tirofiban 2111 Tivozanib 2112 Tizanidine 2113 Tobramycin 2114 Tocainide 2115 Tocilizumab 2116 Tofacitinib 2117 Tolazamide 2118 Tolazoline 2119 Tolbutamide 2120 Tolcapone 2121 Tolfenamic acid 69 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 2122 Tolmetin 2123 Tolonium 2124 Tolpropamine 2125 Tolrestat 2126 Tolterodine 2127 Tolvaptan 2128 Topiramate 2129 Topotecan 2130 Torasemide 2131 Toremifene 2132 Toxoids; for injection 2133 Tramadol 2134 Trametinib dimethyl sulfoxide 2135 Trandolapril 2136 Tranexamic acid 2137 Tranylcypromine 2138 Trastuzumab 2139 Trastuzumab emtansine 2140 Travoprost 2141 Trazodone 2142 Trenbolone 2143 Treosulphan 2144 Treprostinil 2145 Trestolone 2146 Tretamine 2147 Tretinoin 2148 Triacetyloleandomycin 2149 Triamcinolone; except when specified elsewhere in this schedule 2150 Triamterene 2151 Triaziquone 2152 Triazolam 2153 Trichlormethiazide 2154 Trichloroacetic acid; except for external use in medicines containing 12.5% or less for the treatment of warts other than anogenital warts 2155 Trichloroethylene 70 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule 2156 Trichodesma africana; at all strengths 2157 Triclofos 2158 Tricyclamol 2159 Tridihexethyl 2160 Trientine 2161 Trifluoperazine 2162 Trifluperidol 2163 Triflupromazine 2164 Trifluridine 2165 Trimeprazine; except when specified elsewhere in this schedule 2166 Trimetaphan 2167 Trimethoprim; except in medicines for oral use
 containing 300 milligrams or less per dose unit when sold in a pack of 3 solid dosage units to a woman aged 16–65 years for the treatment of an uncomplicated urinary tract infection by a registered pharmacist who has successfully completed the New Zealand Col‐ lege of Pharmacists’ training in the treatment of urinary tract infections 2168 Trimipramine 2169 Trimustine 2170 Trinitrophenol 2171 Trioxysalen 2172 Triparanol; at all strengths 2173 Triple antigen vaccine 2174 Triprolidine; except when specified
 elsewhere in this schedule 2175 Triptorelin 2176 Troglitazone 2177 Trometamol; for injection in medicines containing more than 3% 2178 Tropicamide; except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board 2179 Tropisetron 2180 Trovafloxacin 2181 Troxidone 2182 Tryptophan; except in medicines containing 100 milligrams or less per recom‐ mended daily dose; except in parenteral nutrition replacement preparations 2183 Tuberculin 2184 Tuberculosis vaccine 2185 Tubocurarine 71 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 2186 Tucatinib 2187 Tulobuterol 2188 Typhoid vaccine 2189 Ulipristal 2190 Umeclidinium bromide 2191 Unifiram 2192 Unoprostone 2193 Upadacitinib 2194 Uracil 2195 Urapidil 2196 Urethane 2197 Urofollitropin 2198 Urokinase 2199 Ursodeoxycholic acid 2200 Ustekinumab 2201 Vaccines; except when specified elsewhere in this schedule 2202 Vaccinia virus vaccine 2203 Valaciclovir 2204 Valdecoxib 2205 Valganciclovir 2206 Valnoctamide 2207 Valproic acid 2208 Valsartan 2209 Vancomycin 2210 Vandetanib 2211 Vardenafil and its structural analogues 2212 Varenicline 2213 Varicella vaccine; except when administered for the prevention of herpes zoster (shingles) to a person 50 years of age or over by a registered pharmacist who has successfully completed the Vaccinator Foundation Course (or any equiva‐ lent training course approved by the Ministry of Health) and who complies with the immunisation
 standards of the Ministry of Health (but excluding a vaccinator who has completed the Provisional Vaccinator Foundation Course) 2214 Vasopressin 2215 Vecuronium 2216 Vedolizumab 72 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule 2217 Velaglucerase alfa 2218 Velpatasvir 2219 Vemurafenib 2220 Venetoclax 2221 Venlafaxine 2222 Verapamil 2223 Veratrum spp 2224 Vernakalant 2225 Verteporfin 2226 Veruprevir 2227 Vidarabine 2228 Vigabatrin 2229 Vilanterol 2230 Vildagliptin 2231 Viloxazine 2232 Vinblastine
 2233 Vincamine 2234 Vincristine 2235 Vindesine 2236 Vinflunine 2237 Vinorelbine 2238 Vinyl ether 2239 Virginiamycin 2240 Vismodegib 2241 Visnadine 2242 Vitamin A; except for internal use in medicines containing 3 milligrams or less of retinol equivalents per recommended daily dose; except in parenteral nutri‐ tion replacement preparations; except for external use in medicines containing 1% or less 2243 Vitamin D; except for external use; except for internal use in medicines con‐ taining 25 micrograms or less per recommended daily dose; except in paren‐ teral nutrition replacement preparations 2244 Voglibose 2245 Vorapaxar 2246 Voretigene neparvovec 2247 Voriconazole 73 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 2248 Vorinostat 2249 Vortioxetine 2250 Voxilaprevir 2251 Warfarin 2252 Xamoterol 2253 Xanthinol nicotinate 2254 Ximelagatran 2255 Xipamide 2256 Yellow fever vaccine 2257 Yohimbine 2258 Zafirlukast 2259 Zalcitabine 2260 Zaleplon 2261 Zanamivir 2262 Zidovudine 2263 Zimeldine 2264 Zinc; except for internal use in medicines containing 25 milligrams or less per recommended daily dose; except for internal use in medicines containing 50 milligrams or less and more than 25 milligrams per recommended daily dose in packs that have received the consent of the Minister or the Director- General to their distribution as general sale medicines, when sold in the manu‐ facturer’s original pack and when labelled with a statement that the product may be
 dangerous if taken in large amounts or for long periods; except for external use when in medicines containing 5% or less; except in parenteral nutrition replacement preparations 2265 Ziprasidone 2266 Zoledronic acid 2267 Zolmitriptan; except when specified elsewhere in this schedule 2268 Zolpidem 2269 Zonisamide 2270 Zopiclone 2271 Zoster immunoglobulin, human 2272 Zoxazolamine 2273 Zuclopenthixol 74 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule Part 2
Part 2 Restricted medicines Adrenaline; in medicines containing 1% or less except in medicines for injec‐ tion containing 0.02% or less Alclometasone; for dermal use in medicines containing 0.05% or less and in packs containing not more than 30 grams that have received the consent of the Minister or the Director-General to their distribution as restricted medicines, when sold in the manufacturer’s original pack Aminophylline; for oral use in liquid form in medicines containing 2% or less Amorolfine; for external use in medicines containing more than 0.25% Aspirin; in slow-release forms; in enteric coated forms containing more than 300 milligrams per dose form Azatadine; for oral use in adults and children over 2 years of age Azelastine; in medicines for ophthalmic use containing 0.05% or less Brompheniramine; for oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of insomnia; for oral use for the treatment of insomnia when sold in the manufacturer’s original pack containing not more than 10 dosage units Buclizine; for oral use Butoconazole; for vaginal use Chloramphenicol; for ophthalmic use; except when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board Chlorbutol; except when specified elsewhere in this schedule Chlorpheniramine; for oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of insomnia; for
 oral use for the treatment of insomnia when sold in the manufacturer’s original pack containing not more than 10 dosage units Ciclopirox; for external use in medicines containing more than 2%; in prepar‐ ations for application to the nails containing more than 8% Cimetidine; in medicines for the symptomatic relief of heartburn, dyspepsia, and hyperacidity or to be used on the recommendation of a registered medical practitioner, when sold in the manufacturer’s original pack containing not more than 14 days’
 supply Clemastine; for oral use Clobetasone; for dermal use in medicines containing 0.05% or less and in packs containing not more than 30 grams that have received the consent of the Minister or the Director-General to their distribution as restricted medicines, when sold in the manufacturer’s original pack 18 Clotrimazole; for vaginal use 75 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 Cyclizine; for oral use other than in medicines used for the treatment of insom‐ nia when sold in the manufacturer’s original pack containing not more than 6 dosage units; for oral use in medicines used for the treatment of insomnia when sold in the manufacturer’s original pack containing not more than 10 dosage units Cyproheptadine; for oral use Dexchlorpheniramine; for oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of insomnia; for oral use for the treatment of insomnia when sold in the manufacturer’s original pack containing not more than 10 dosage units Dextromethorphan; in liquid form when in packs containing not more than 600 milligrams and with a recommended daily dose of not more than 120 milli‐ grams; in medicines for the treatment of symptoms of cough and cold in adults and children aged six years and over Di-iodohydroxy quinoline; for vaginal use Diclofenac; in solid dose form in medicines containing 25 milligrams or less and more than 12.5 milligrams per dose form in packs containing not
 more than 30 tablets or capsules Dimenhydrinate; for oral use in medicines for adults and children over 2 years of age; except when specified elsewhere in this schedule Dimethindene; for oral use Diphenhydramine; for oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of insomnia; for oral use for the treatment of insomnia when sold in the manufacturer’s original pack containing not more than 10 dosage units Dithranol Doxylamine; for oral use in
 medicines for adults or children over 2 years of age other than in medicines used for the treatment of insomnia; for oral use for the treatment of insomnia when sold in the manufacturer’s original pack containing not more than 10 dosage units Econazole; for vaginal use Erythrityl tetranitrate Famciclovir; in divided solid dosage forms for oral use containing 500 milli‐ grams or less for the treatment of recurrent herpes labialis when sold in the manufacturer’s original pack containing up to 3 dosage units Flavoxate Fluconazole; for oral use in medicines that have received the consent of the Minister or the Director-General to their distribution as restricted medicines, when sold in the manufacturer’s original pack containing 150 milligrams or less as a single dose for the treatment of vaginal candidiasis 26 27 28 29 30 31 32 33 34 76 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule 35 36 37 38 39 40 41 42 43 44 Fluorides; for external use in liquid form in medicines containing 5.5 grams or less and more than 1 gram per litre or per kilogram and when sold in packs approved by the Minister or the Director-General for distribution as restricted medicines; for external use in non-liquid form in medicines containing 5.5 grams or less and more than 1 gram per litre or per kilogram, except in medicines containing 1.5 grams or less and more than 1 gram per litre or per kilogram; except when supplied to a dental professional registered with
 the Dental Council Glucagon; except in medicines containing 100 micrograms or less per litre or per kilogram Glyceryl trinitrate; for oral or sublingual use; for rectal use Guaifenesin; for oral use in modified release form with a maximum recommen‐ ded daily dose of not more than 2.4 grams when sold in the manufacturer’s ori‐ ginal pack containing more than 10 days’ supply but not more than 30 days’ supply; except for oral use in modified release form with a maximum recom‐ mended daily dose of not more than
 2.4 grams when sold in the manufacturer’s original pack containing not more than 10 days’ supply; except for oral use in medicines containing 2% or less or 200 milligrams or less per dose form Haemophilus influenzae vaccine; in oral vaccines for the prophylaxis of bacte‐ rial complications of colds Hydrocortisone and hydrocortisone acetate but no other esters of hydrocorti‐ sone; for dermal use in medicines containing 1% or less but more than 0.5% by weight of hydrocortisone base with no other active ingredient except an anti‐ fungal and in a quantity of 30 grams or less or 30 millilitres or less per con‐ tainer; for dermal use in medicines containing 1% or less but more than 0.5% by weight of hydrocortisone base with no other active ingredient except 5% or less by weight of aciclovir and in a quantity of 2 grams or less or 2 millilitres or less per container in adults and children 12 years of age and older; in rectal medicines containing 1% or less but more than 0.5% by weight of hydrocorti‐ sone base and in combination with a local anaesthetic and in a quantity of 35 grams or less per container or up to 12 suppositories per pack Hyoscine butylbromide; for oral use in medicines containing not more than 20 milligrams per dose form and in packs containing not more than 10 tablets or capsules for the relief of muscle spasm of the gastrointestinal tract Ibuprofen; for oral use in tablets or capsules containing up to 400 milligrams per dose form and in packs
 containing not more than 50 dose units and that have received the consent of the Minister or the Director-General to their distri‐ bution as restricted medicines, when sold in the manufacturer’s original pack labelled for use by adults or children over 12 years of age Inositol nicotinate Isoconazole; for vaginal use 77 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 45 46 Ketoprofen; in solid dose form containing 25 milligrams or less per dose form in packs of not more than 30 capsules or tablets
 Lansoprazole; in divided solid dosage forms for oral use containing 15 milli‐ grams or less with a maximum daily dose of 15 milligrams for the short-term symptomatic relief of gastric reflux-like symptoms in sufferers aged 18 years and over for the relief of heartburn when sold in the manufacturer’s original pack containing not more than 14 dosage units 47 Levonorgestrel; in medicines for use as emergency post-coital contraception when in packs containing not more than 1.5 milligrams 48 Macrogols; in oral preparations for bowel cleansing prior to diagnostic, med‐ ical, or surgical procedures 49 Malathion; except for external use in medicines containing 2% or less 50 Mannityl hexanitrate 51 Meclozine; in a pack size of up to 10 dosage units for the treatment of insom‐ nia 52 Mepyramine; for oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of insomnia; for oral use for the treatment of insomnia when sold in the manufacturer’s original pack con‐ taining not more than 10 dosage units 53 Methdilazine; for oral use 54 Metoclopramide; when compounded with paracetamol in packs of not more than 10 tablets or capsules for the treatment of nausea associated with migraine 55 Miconazole; for the treatment of oral candidiasis; for vaginal use Nicotinic acid except nicotinamide; in medicines containing 250 milligrams or less but more than 100 milligrams per dose form; except in medicines contain‐ ing 100 milligrams
 or less per dose form Nicotinyl alcohol; except in medicines containing 100 milligrams or less per dose form Nystatin; for the treatment of oral candidiasis; for vaginal use Orlistat; in medicines for weight control containing 120 milligrams or less per dose form Oseltamivir; in solid dosage forms for oral use containing 75 milligrams in a pack size of up to 10 dosage units for the treatment or prophylaxis of influenza in adults and children aged 13 years and older who have been exposed to the influenza
 virus Oxiconazole; for vaginal use Paracetamol; in modified-release forms containing 665 milligrams or less Pheniramine; for oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of insomnia; for oral use for 56 57 58 59 60 61 62 63 78 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule the treatment of insomnia when sold in the manufacturer’s original pack con‐ taining not more than 10 dosage units Pneumococcal vaccine; in oral vaccines for the prophylaxis of bacterial com‐ plications of colds Podophyllotoxin; for external use for the treatment of warts other than anogeni‐ tal warts in medicines containing 1% or less and more than 0.5%; except in medicines containing 1 milligram or less of podophyllin per litre or per kilo‐ gram Podophyllum emodi; for external use for the treatment of warts other than ano‐ genital warts in medicines containing 20% or less and more than 10% of podo‐ phyllin; except in medicines containing 1 milligram or less of podophyllin per litre or per kilogram Podophyllum peltatum; for external use for the treatment of warts other than anogenital warts in medicines containing 20% or less and more than 10% of podophyllin; except in medicines containing 1 milligram or less of podophyllin per litre or per kilogram Prochlorperazine; in packs containing not more than 10 tablets or capsules for the treatment of nausea associated with migraine Promethazine; for oral use in
 medicines for adults or children over 2 years of age other than in medicines used for the treatment of insomnia; for oral use for the treatment of insomnia when sold in the manufacturer’s original pack con‐ taining not more than 10 dosage units Rizatriptan; for oral use in medicines for the acute relief of migraine attacks with or without aura in patients who have a stable, well-established pattern of symptoms, when in wafers containing 5 milligrams or less per wafer and when sold in a pack containing not more
 than 2 wafers approved by the Minister or the Director-General for distribution as a restricted medicine Salicylic acid; except in medicines for dermal use containing 40% or less Santonin Sodium phosphate; in oral preparations for bowel cleansing prior to diagnostic, medical, or surgical procedures Sodium picosulphate; in oral preparations for bowel cleansing prior to diagnos‐ tic, medical, or surgical procedures Staphyloccocus aureus vaccine; in oral vaccines for the prophylaxis of bacterial complications of colds Stramonium; for oral use in liquid form; in solid dose form in medicines con‐ taining more than 0.3 milligrams per dose or more than 1.2 milligrams per rec‐ ommended daily dose Streptococcus beta-haemolyticus vaccine; in oral vaccines for the prophylaxis of bacterial complications of colds 64 65 66 67 68 69 70 71 72 73 74 75 76 77 79 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 Sulfacetamide; for ophthalmic use in medicines containing 10% or less Sumatriptan; for oral use in medicines for the acute relief of migraine attacks with or without aura in patients who have a stable, well-established pattern of symptoms when in tablets containing 50 milligrams or less per tablet and when sold in a pack containing not more than 2 tablets that has received the consent of the Minister or the Director-General to its sale as a restricted medicine Theophylline; in liquid form for oral use in medicines containing 2% or less Tioconazole; for vaginal
 use Triamcinolone; for buccal use in medicines containing 0.1% or less of triamci‐ nolone acetonide and in pack sizes of 5 grams or less Trimeprazine; for oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of insomnia; for oral use for the treatment of insomnia when sold in the manufacturer’s original pack con‐ taining not more than 10 dosage units Triprolidine; for oral use in medicines for adults and children over 2 years of age; except when
 specified elsewhere in this schedule Zolmitriptan; in a pre-filled nasal spray device containing not more than 5 mil‐ ligrams of zolmitriptan, for the acute relief of migraine attacks with or without aura in patients who have a stable, well-established pattern of symptoms and when sold in a pack of not more than 2 devices approved by the Minister or the Director-General for distribution as a restricted medicine Part 3 Pharmacy-only medicines 8-hydroxyquinoline and its non-halogenated derivatives; in medicines contain‐ ing more than 1% of such substances; except for hydroxyquinoline sulphate for external use Acetic acid and preparations containing more than 80% of acetic acid (CH3COOH); excluding its salts and derivatives Acetylcysteine; for oral use in medicines containing more than 1 gram per rec‐ ommended daily dose Aciclovir; for external use for the treatment of herpes labialis except in medi‐ cines containing 5% or less and in tubes containing 10 grams or less Aconitum spp; for oral use in packs containing 0.2 milligrams or less and more than 0.02 milligrams of total alkaloids; for dermal use in concentrations of 0.02% or less and in packs containing 0.2 milligrams or less and more than 0.02 milligrams of total alkaloids Aloes; for internal use; except when obtained solely from the mucilaginous gel of the leaf Aloin 78 79 80 81 82 83 84 85 80 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule Aloxiprin
Schedule Aloxiprin Amethocaine; for external use in medicines containing 10% or less and more than 2%; except in medicines for external use containing 2% or less Amorolfine; in preparations for topical use; except in preparations for the treat‐ ment of tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board Antazoline; for ophthalmic use except when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board Atropa belladonna; for external use in
 medicines containing 0.03% or less of the alkaloids of belladonna; for oral use in liquid form in medicines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milli‐ grams per recommended daily dose of the alkaloids of belladonna or in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose of the alkaloids of bel‐ ladonna Atropine; for oral use in liquid form in medicines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milligrams per recom‐ mended daily dose or in solid dose form in medicines containing 0.3 milli‐ grams or less per dose form and not more than 1.2 milligrams per recommen‐ ded daily dose; in medicines containing atropine sulphate for the treatment of organophosphorus poisoning either in packs of not more than 20 dose units containing 0.6 milligrams or less per dose unit or in injections in packs of not more than 5 vials containing 0.6 milligrams per millilitre; except when sold as an antidote in a device designed for self-injection from outlets licensed to sell organophosphorus poisons; except in medicines containing 300 micrograms or less per litre or per kilogram Azelaic acid; for dermal use Azelastine; in preparations for nasal use containing 0.15% azelastine hydro‐ chloride or less; in topical eye preparations containing 0.05% or less Beclomethasone; for the treatment or prophylaxis of allergic
 rhinitis in adults and children over 12 years of age in aqueous nasal sprays delivering up to 50 micrograms per actuation when the maximum recommended daily dose is no greater than 400 micrograms (200 micrograms per nostril) in a pack con‐ taining 200 actuations or less Benzocaine; in preparations for topical use, other than eye drops, containing 10% or less of total anaesthetic substances except in dermal preparations con‐ taining 2% or less of total anaesthetic substances; in divided preparations con‐ taining
 200 milligrams or less of total anaesthetic substances per dosage unit except in lozenges containing 30 milligrams or less of total anaesthetic sub‐ stances per dosage unit 18 Benzoyl peroxide; for external use in medicines containing more than 5% and not more than 10%; except for medicines for external use containing 5% or less 81 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 26 27 28 29 30 31 32 33 34 Benzydamine; for external use except for oromucosal or topical use Bephenium Bifonazole; except when specified elsewhere in this schedule; except for der‐ mal use in medicines for tinea pedis only or in shampoos containing 1% or less or when sold in practice by a podiatrist registered with the Podiatrists Board Bilastine; in divided solid dosage forms for oral use containing 20 milligrams or less for the treatment of the symptoms of allergic rhinoconjunctivitis (sea‐ sonal and perennial) Bisacodyl Bromhexine Brompheniramine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other thera‐ peutically active ingredients either when in the bedtime dose of a day/night pack containing brompheniramine or when at least 1 of the other active ingre‐ dients is a sympathomimetic decongestant Budesonide; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age in aqueous nasal sprays delivering up to 64 micrograms per actuation and
 when the maximum recommended daily dose is no greater than 400 micrograms (200 micrograms per nostril) Carbetapentane; except in medicines containing 0.5% or less Carbocisteine Cetirizine; for oral use except in divided solid dosage forms for oral use con‐ taining 10 milligrams or less of cetirizine hydrochloride per dose form for the treatment of seasonal allergic rhinitis when sold in the manufacturer’s original pack containing not more than 5 days’ supply Chlophedianol Chlorbutol; in medicines
 containing 5% or less and more than 0.5%; except in medicines containing 0.5% or less Chloroform; in medicines other than for anaesthesia containing more than 0.5%; except in medicines containing 0.5% or less Chlorpheniramine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other thera‐ peutically active ingredients either when in the bedtime dose of a day/night pack containing chlorpheniramine or when at least 1 of the other active ingredi‐ ents is a sympathomimetic decongestant Ciclopirox; for external use in medicines containing 2% or less except when for the treatment of tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board; in preparations for application to the nails containing 8% or less 35 Cinchocaine; for external use in medicines containing 0.5% or less 82 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule 36 37 38 39 40 41 42 43 44 45 46 47 48 49 Cinnamedrine Clotrimazole; for external use except in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board Cocaine; in medicines for oral use, containing not more than 0.1% of cocaine, when combined with 1 or more active ingredients in such a way that the sub‐ stance cannot be recovered by readily applicable means or in a yield that would constitute a risk to health, and when sold in a pack approved by the Minister or the
 Director-General for distribution as a pharmacy-only medicine Colocynth Creosote; except in medicines containing 10% or less Cresols; except in medicines containing 3% or less Datura spp; for oral use in liquid form in medicines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milligrams per rec‐ ommended daily dose of total solanaceous alkaloids; in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily
 dose of total solanaceous alkaloids Delphinium staphisagria; except in medicines containing 0.2% or less Desloratadine; for oral use Dexchlorpheniramine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other thera‐ peutically active ingredients either when in the bedtime dose of a day/night pack containing dexchlorpheniramine or when at least 1 of the other active ingredients is a sympathomimetic decongestant Dextromethorphan; in liquid form containing more than 0.25% or in solid dose form containing more than 15 milligrams per dose form when in packs contain‐ ing not more than 600 milligrams and with a recommended daily dose of not more than 120 milligrams; in medicines for the treatment of the symptoms of cough and cold in children aged 6–12 years; except in liquid form containing 0.25% or less in solid dose form containing 15 milligrams or less per dose form when in packs containing not more than 600 milligrams and with a recommen‐ ded daily dose of not more than 120 milligrams Dibrompropamidine; for ophthalmic use except when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board Diclofenac; in solid dose form in medicines containing 12.5 milligrams or less per dose form in packs containing not more than 30 tablets or capsules and with a recommended daily dose of not more than 75 milligrams Diphenoxylate; in liquid form containing in each
 millilitre not more than 0.5 milligrams of diphenoxylate calculated as base and not less than 5 micro‐ grams of atropine sulphate; in solid dose form containing not more than 2.5 milligrams of diphenoxylate calculated as base and not less than 5 micro‐ grams of atropine sulphate 83 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 Dimenhydrinate; for oral use in a sealed container of not more than 10 tablets or capsules for the prevention or treatment of motion sickness in adults or chil‐ dren over 2
 years of age except when sold at a transport terminal or aboard a ship or an aircraft Diphenhydramine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other thera‐ peutically active ingredients either when in the bedtime dose of a day/night pack containing diphenhydramine or when at least 1 of the other active ingredi‐ ents is a sympathomimetic decongestant; for oral use in a sealed container of not more than 10 tablets or capsules for the prevention or treatment of motion sickness in adults and children over 2 years of age except when sold at a trans‐ port terminal or aboard a ship or an aircraft Doxylamine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other therapeutically active ingredients either when in the bedtime dose of a day/night pack contain‐ ing doxylamine or when at least 1 of the other active ingredients is a sympatho‐ mimetic decongestant Duboisia leichhardtii; for oral use in liquid form in medicines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milli‐ grams per recommended daily dose of total solanaceous alkaloids; in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids Duboisia myoporides; for oral use in liquid form in medicines containing 0.03% or
 less and 0.3 milligrams or less per dose and not more than 1.2 milli‐ grams per recommended daily dose of total solanaceous alkaloids; in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids Econazole; for dermal use except in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board Esomeprazole; in oral preparations containing 20
 milligrams or less per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days’ supply Etafedrine Ether; in medicines containing more than 10%; except in medicines containing 10% or less Etofenamate; for external use Famotidine; for the symptomatic relief of heartburn, dyspepsia, and hyperacid‐ ity or to be used on the recommendation of a registered medical practitioner, when sold in the manufacturer’s original pack containing not more than 14 days’ supply 50 51 52 53 54 55 56 57 58 59 60 84 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule 61 62 63 64 65 66 67 68 69 70 71 Felbinac; for external use Fexofenadine; for oral use except for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when in capsules containing 60 milligrams or less of fexofenadine hydrochloride or in tablets containing 120 milligrams or less of fexofenadine hydrochloride with a maximum daily dose of 120 milligrams when sold in the manufacturer’s original pack contain‐ ing 20 dosage units or less and not more than 10 days’ supply; for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when in tablets containing 180 milligrams or less of fexofenadine hydrochlor‐ ide with a maximum daily dose of 180 milligrams when sold in the manufac‐ turer’s original pack containing 5 dosage units or less and not more than 5 days’
 supply Fluorides; for internal use in medicines containing 0.5 milligrams or less per dose unit; except in parenteral nutrition replacement preparations; for external use in liquid form in medicines containing 1 gram or less per litre or per kilo‐ gram and when sold in packs approved by the Minister or the Director-General for distribution as pharmacy-only medicines except in medicines containing 220 milligrams or less per litre or per kilogram and in packs containing not more than 120 milligrams of total
 fluoride; except when supplied to any dental professional registered with the Dental Council; except in medicines containing 15 milligrams or less per litre or per kilogram Flurbiprofen; in locally acting oromucosal preparations containing 10 milli‐ grams or less per dosage unit Fluticasone; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age when in aqueous nasal sprays delivering up to 50 micrograms per actuation with a maximum recommended daily dose of 200 micrograms (as a single dose) Folic acid; for oral use in medicines containing more than 500 micrograms per recommended daily dose; except for oral use in medicines containing 500 micrograms or less per recommended daily dose; except in parenteral nutrition replacement preparations Folinic acid; for oral use in medicines containing more than 500 micrograms per recommended daily dose; except for oral use in medicines containing 500 micrograms or less per recommended daily dose Formaldehyde; except in medicines containing 5% or less Gelsemium sempervirens; except in medicines containing 1 milligram or less per litre or per kilogram Glutaraldehyde Hexachlorophane; in medicines containing 3% or less but more than 0.75%; except in medicines containing 0.75% or less 85 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 Hydrocortisone and hydrocortisone acetate but no other esters of hydrocorti‐ sone; for dermal use in medicines containing 0.5% or less by
 weight of hydro‐ cortisone base with no other active ingredient except an antifungal and in a quantity of 30 grams or less or 30 millilitres or less per container; in rectal medicines containing 0.5% or less by weight of hydrocortisone base and in combination with a local anaesthetic and in a quantity of 35 grams or less per container or 12 suppositories or fewer per pack Hydrocyanic acid; for oral use in packs containing 5 milligrams or less and more than 0.5 milligrams; except in medicines containing 1
 microgram or less per litre or per kilogram; except for oral use in packs containing 0.5 milligrams or less Hydroquinone; for external use in medicines containing 2% or less except in hair preparations containing 1% or less Hyoscine; for transdermal use in medicines containing 2 milligrams or less of total solanaceous alkaloids per dose unit; for oral use in liquid form in medi‐ cines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids; in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids Hyoscyamine; for external use in medicines containing 0.03% or less of total solanaceous alkaloids; for oral use in liquid form in medicines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milli‐ grams per recommended daily dose of total solanaceous alkaloids; in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids Hyoscyamus niger; for oral use in liquid form in medicines containing 0.03% or less (300 micrograms or less of total solanaceous alkaloids per litre or per kilogram) and 0.3 milligrams or less per dose and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids or in solid
 dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose except in packs contain‐ ing 30 micrograms or less of total solanaceous alkaloids Ibuprofen; for oral use in liquid form with a recommended daily dose of not more than 1.2 grams for the relief of pain and reduction of fever or inflamma‐ tion when sold in the manufacturer’s original pack containing not more than 8 grams; for oral use in solid dose form containing not more than 200
 milli‐ grams per dose form and with a recommended daily dose of not more than 1.2 grams when sold in the manufacturer’s original pack containing not more than 100 dose units; except in divided solid dosage forms for oral use contain‐ ing 200 milligrams or less per dose form with a recommended daily dose of not 72 73 74 75 76 77 78 86 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule 79 80 81 82 83 84 85 86 87 88 89 90 91 92 more than 1.2 grams and when sold in the manufacturer’s original pack con‐ taining not more than 25 dose units; except for external use Indanazoline Indomethacin; for external use in medicines containing 1% or less; except in medicines containing 1 milligram or less per litre or per kilogram Iodine; except for external use in medicines containing 2.5% or less; for inter‐ nal use in medicines containing less than 300 micrograms per recommended daily dose Ipecacuanha; in medicines containing 0.2% or less of emetine and 40 micro‐ grams or more of ipecacuanha alkaloids per recommended dose for the treat‐ ment of the symptoms of cough and cold in children aged 6–12 years; except in medicines containing less than 40 micrograms of ipecacuanha alkaloids per recommended dose for the treatment of the symptoms of cough and cold in children aged 6–12 years Ipomoea spp; except ipomoea batatas Ipratropium; for nasal use Iron; for oral use either in medicines containing more than 24 milligrams per recommended daily dose or in medicines containing
 more than 5 milligrams per dose unit and more than 750 milligrams of iron per pack; except in paren‐ teral nutrition replacement preparations; except for oral use in medicines con‐ taining 24 milligrams or less per recommended daily dose in medicines con‐ taining not more than 5 milligrams per dose unit; except for oral use in medi‐ cines containing 24 milligrams or less per recommended daily dose in medi‐ cines containing more than 5 milligrams per dose unit in packs containing not more than 750
 milligrams of iron Isoconazole; for dermal use except when sold in practice by a podiatrist regis‐ tered with the Podiatrists Board Isopropamide; for dermal use in preparations containing 2% or less Jalap resin Ketoconazole; for dermal use except in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board; except in medicines for treatment of the scalp containing 1% or less Ketotifen; for ophthalmic use in medicines containing 0.025% or less except when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board Leucovorin; in medicines containing more than 500 micrograms per recom‐ mended daily dose Levocabastine; for nasal use; for ophthalmic use except when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board 87 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 93 94 95 96 97 98 99 Levocetirizine; for oral use Lignocaine; for urethral use; for external use in medicines containing 10% or less and more than 2% Lindane; for external use in medicines containing 2% or less Lithium; for dermal use in medicines containing 1% or less but more than 0.01%; except for dermal use in medicines containing 0.01% or less Lobelia inflata; except in medicines for smoking or burning Lobeline; except when in medicines for smoking or burning Lodoxamide; for ophthalmic use except when sold in practice by an optomet‐ rist registered
 with the Optometrists and Dispensing Opticians Board 100 Loperamide; in packs containing not more than 20 tablets or capsules; except in divided solid dosage forms for oral use containing 2 milligrams or less of loperamide per dosage form when sold in a pack containing not more than 8 dosage forms approved by the Minister or the Director-General for distribution as a general sales medicine for the symptomatic treatment of acute non-specific diarrhoea 101 Loratadine; for oral use; except in divided solid
 dosage forms for oral use con‐ taining 10 milligrams or less per dose form for the treatment of seasonal aller‐ gic rhinitis when sold in the manufacturer’s original pack containing not more than 10 days’ supply 102 Macrogols; in preparations for oral use as a liquid concentrate for laxative use 103 Mebendazole 104 Meclozine; in a sealed container of not more than 12 tablets or capsules for the prevention or treatment of travel sickness except when sold at a transport ter‐ minal or aboard a ship or aircraft 105 Mefenamic acid; in solid dose form in packs containing not more than 30 tab‐ lets or capsules for the treatment of dysmenorrhoea 106 Mepyramine; for dermal use; except for external use in medicines containing 2% or less in packs not exceeding 25 grams 107 Mercuric oxide; for ophthalmic use 108 Mercurochrome; in preparations for external use containing 2% or less 109 Mercury; for external use in medicines containing 0.5% or less; except in med‐ icines containing 1 milligram or less per litre or per kilogram 110 Methoxamine; for external use in medicines containing more than 1%; except for external use in medicines containing 1% or less 111 Methoxyphenamine 112 Methylephedrine 113 Miconazole; for external use except in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board 88 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule 114 Minoxidil; for dermal use in medicines containing 5% or less
 115 Mometasone; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age in aqueous nasal sprays delivering up to 50 micrograms per actuation when the maximum recommended daily dose is no greater than 200 micrograms (as a single dose) in a pack containing 200 actuations or less 116 Morphine; in medicines for oral use containing not more than 0.2% of mor‐ phine, when combined with 1 or more active ingredients in such a way that the substance cannot be recovered by
 readily applicable means or in a yield that would constitute a risk to health, when sold in a pack approved by the Minister or the Director-General for distribution as a pharmacy-only medicine 117 Naphazoline; except for ophthalmic use when sold in practice by an optomet‐ rist registered with the Optometrists and Dispensing Opticians Board 118 Naproxen; in solid dose form containing 250 milligrams or less per dose form in packs of not more than 30 tablets or capsules 119 Niclosamide 120 Nicotine; for inhalation except when sold from a smoking cessation clinic run under the auspices of a registered medical practitioner, nurse, pharmacist, or psychologist 121 Nizatidine; in medicines for the symptomatic relief of heartburn, dyspepsia, and hyperacidity or to be used on the recommendation of a registered medical practitioner, when sold in the manufacturer’s original pack containing not more than 14 days’ supply 122 Noscapine 123 Nystatin; for dermal use except when sold in practice by a podiatrist registered with the Podiatrists Board; except in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board 124 Omeprazole; in divided solid dosage forms for oral use containing 20 milli‐ grams or less with a maximum daily dose of 20 milligrams for the short-term symptomatic relief of gastric reflux-like symptoms in sufferers aged 18 years and over when sold in the manufacturer’s original pack containing not more than 28
 dosage units 125 Opium; in medicines for oral use containing not more than 0.2% of morphine, when combined with 1 or more active ingredients in such a way that the sub‐ stance cannot be recovered by readily applicable means, or in a yield that would constitute a risk to health, when sold in a pack approved by the Minister or the Director-General for distribution as a pharmacy-only medicine 126 Oxetacaine; for internal use 127 Oxiconazole; for dermal use except in medicines for tinea pedis only 89 Schedule
 Medicines Amendment Regulations (No 2) 2021 2021/228 128 Oxymetazoline; except for nasal use when sold at an airport; except for oph‐ thalmic use when sold in practice by an optometrist registered with the Optom‐ etrists and Dispensing Opticians Board; except for nasal use in medicines con‐ taining 0.05% or less when sold in the manufacturer’s original pack with a pack size of 20 millilitres or less 129 Pantoprazole; in divided solid dosage forms for oral use containing 20 milli‐ grams or less with a maximum daily dose of 20 milligrams for the short-term symptomatic relief of gastric reflux-like symptoms in sufferers aged 18 years and over when sold in the manufacturer’s original pack containing not more than 28 dosage units 130 Papaverine; except for injection 131 Paracetamol; in liquid form; in suppositories; in tablets or capsules containing 500 milligrams or less and in packs containing more than 10 grams and not more than 50 grams; in powder form containing not more than 1 gram per sachet and more than 10 grams per pack; except in tablets or capsules contain‐ ing 500 milligrams or less and in packs containing not more than 10 grams; except in powder form in sachets containing 1 gram or less and in packs of not more than 10 grams 132 Paraformaldehyde; except in medicines containing 5% or less 133 Penciclovir; for external use for the treatment of herpes labialis; except in med‐ icines for external use containing 1% or less in a pack containing 10 grams or less
 for the treatment of herpes labialis 134 Phedrazine 135 Phenazone; for external use 136 Pheniramine; for ophthalmic use except when sold in practice by an optomet‐ rist registered with the Optometrists and Dispensing Opticians Board; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other therapeutically active ingredients either when in the bedtime dose of a day/night pack containing pheniramine or when at least 1 of the other active
 ingredients is a sympathomimetic decongest‐ ant 137 Phenol; except in medicines other than for injection containing 3% or less 138 Phenylephrine; for nasal use in medicines containing more than 1%; for oph‐ thalmic use in medicines containing 5% or less and more than 1%; for oral use in medicines containing more than 50 milligrams per recommended daily dose or in packs containing more than 250 milligrams of phenylephrine per pack; in medicines for the treatment of the symptoms of cough and cold in children aged 6–12 years; except for nasal or ophthalmic use in medicines containing 1% or less; except for oral use in medicines containing 50 milligrams or less per recommended daily dose and in packs containing 250 milligrams or less of phenylephrine per pack 90 2021/228 Medicines Amendment Regulations (No 2) 2021 Schedule 139 Pholcodine; in medicines for oral use containing not more than 15 milligrams of pholcodine per solid dosage unit or per dose of liquid with a maximum daily dose not exceeding 100 milligrams of pholcodine, when combined with 1 or more active ingredients in such a way that the substance cannot be recovered by readily applicable means, or in a yield that would constitute a risk to health, when sold in a pack approved by the Minister or the Director-General for dis‐ tribution as a pharmacy-only medicine 140 Piperazine 141 Podophyllotoxin; for external use for the treatment of warts other than anogeni‐ tal warts in medicines containing 0.5% or less; except in
 medicines containing 1 milligram or less of podophyllin per litre or per kilogram 142 Podophyllum emodi; for external use for the treatment of warts other than ano‐ genital warts in medicines containing 10% or less of podophyllin; except in medicines containing 1 milligram or less of podophyllin per litre or per kilo‐ gram 143 Podophyllum peltatum; for external use for the treatment of warts other than anogenital warts in medicines containing 10% or less of podophyllin; except in medicines containing 1
 milligram or less of podophyllin per litre or per kilo‐ gram 144 Potassium; for internal use: in slow-release or enteric coated forms; except for internal use: in medicines containing 100 milligrams or less per recommended dose; in medicines containing more than 100 milligrams per recommended dose except in medicines for oral rehydration therapy, parenteral nutrition replacement, or dialysis; except in glucosamine sulphate complexed products containing 600 milligrams or less of potassium chloride per recommended dose; except for external use 145 Potassium chlorate; except in medicines containing 10% or less 146 Prilocaine; for dermal use in medicines containing 10% or less of local anaes‐ thetic substances 147 Procyclidine; for dermal use in medicines containing 5% or less 148 Promethazine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other therapeutically active ingredients either when in the bedtime dose of a day/night pack contain‐ ing promethazine or when at least 1 of the other active ingredients is a sympa‐ thomimetic decongestant; for oral use in a sealed container of not more than 10 tablets or capsules for the prevention or treatment of motion sickness in adults and children over 2 years of age except when sold at a transport terminal or aboard a ship or aircraft 149 Propamidine; for ophthalmic use except when sold in practice by an optomet‐ rist registered with the Optometrists
 and Dispensing Opticians Board 150 Pyrantel 91 Schedule Medicines Amendment Regulations (No 2) 2021 2021/228 151 Pyrethrins; except in medicines containing 10% or less 152 Pyrithione zinc; except in medicines for treatment of the scalp containing 2% or less 153 Ranitidine; in medicines for the symptomatic relief of heartburn, dyspepsia, and hyperacidity or to be used on the recommendation of a registered medical practitioner when sold in the manufacturer’s original pack containing not more than 14 days’
 supply; except in medicines containing 300 milligrams or less per dose unit when sold in the manufacturer’s original pack containing not more than 7 days’ supply 154 Salicylamide 155 Selenium; for oral use in medicines containing 300 micrograms or less and more than 150 micrograms per recommended daily dose; for external use except in medicines containing 3.5% or less of selenium sulphide 156 Sennosides 157 Silver; except in oral solutions containing 0.3% or less or other medicines con‐ taining 1% or less 158 Silver sulfadiazine; for external use in pack sizes of 50 grams or less 159 Sodium cromoglycate; for nasal use; for ophthalmic use except when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board 160 Sodium nitrite; except for use as an excipient 161 Sodium picosulphate; in oral laxative preparations 162 Squill; except in medicines containing 1% or less 163 Stramonium; for oral use in liquid form in medicines containing 0.03% or less and 0.3 milligrams or less per dose and not more than 1.2 milligrams per rec‐ ommended daily dose of total solanaceous alkaloids; in solid dose form in medicines containing 0.3 milligrams or less per dose form and not more than 1.2 milligrams per recommended daily dose of total solanaceous alkaloids 164 Sulconazole; for dermal use 165 Sulfadiazine, silver; for external use in pack sizes of 50 grams or less 166 Terbinafine; for dermal use except in medicines for tinea pedis only or
 when sold in practice by a podiatrist registered with the Podiatrists Board 167 Tetrachloroethylene 168 Tetrahydrozoline; except for ophthalmic use when sold in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board 169 Thiabendazole 170 Tioconazole; for dermal use except in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board 171 Tramazoline 92 2021/228 Medicines Amendment Regulations (No 2) 2021 Explanatory note 172
 Triamcinolone; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age and when in aqueous nasal sprays delivering up to 55 micrograms per actuation when the maximum recommended daily dose is no greater than 220 micrograms and the medicine has received the consent of the Minister or the Director-General to its distribution as a pharmacy-only medicine 173 Trimeprazine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other therapeutically active ingredients either when in the bedtime dose of a day/night pack contain‐ ing trimeprazine or when at least 1 of the other therapeutically active ingredi‐ ents is a sympathomimetic decongestant 174 Triprolidine; for oral use in medicines for adults and children over 6 years of age when combined in the same container with 1 or more other therapeutically active ingredients either when in the bedtime dose of a day/night pack contain‐ ing triprolidine or when at least 1 of the other active ingredients is a sympatho‐ mimetic decongestant 175 Tuaminoheptane 176 Tymazoline 177 Xylenols; except in medicines containing 3% or less 178 Xylometazoline; except for nasal use when sold at an airport; except for oph‐ thalmic use when sold in practice by an optometrist registered with the Optom‐ etrists and Dispensing Opticians Board 179 Zinc chloride; for dermal use in medicines containing more than 5% Michael Webster, Clerk of the Executive Council.
Explanatory note This note is not part of the regulations, but is intended to indicate their general effect.

These regulations, which come into force on 1 September 2021, replace Schedule 1 of the Medicines Regulations 1984 (the principal regulations).

New Schedule 1 sets out an updated list of specified medicines and classes of medicines that are declared to be prescription medicines, restricted medicines, or pharmacy-only medicines under the Medicines Act 1981 (the Act).
The updated list includes medicines that the Minister of Health has classified by Gaz‐ ette notice made under section 106 of the Act (see Classification of Medicines (Gaz‐ ette 2021-go2170)).
Gazette notices made under section 106 override any inconsistent classification of medicines in the principal regulations, but they do not amend the 93 Explanatory note Medicines Amendment Regulations (No 2) 2021 2021/228 principal regulations, and they cease to have effect after a period of 6 months (if not revoked sooner).

Issued under the authority of the Legislation Act 2012.

Date of notification in Gazette: 31 August 2021.

These regulations are administered by the Ministry of Health.
Wellington, New Zealand: Published under the authority of the New Zealand Government—2021 94